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Highlights
 This study constitutes the largest overview of GHB and derivatives’ mortality data
 UK GHB/GBL deaths still occur despite the substances being illegal
 This paper demonstrates how GHB/GBL fatalities can be identified with appropriate methods
 Mean post-mortem blood levels are twice as high where GHB/GBL alone or with alcohol is used
 More awareness is needed of potentially fatal outcomes using GHB/GBL
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Abstract
Misuse of gamma hydroxybutrate (GHB) and gamma butyrolactone (GBL) has increased greatly since the 
early 1990s, being implicated in a rising number of deaths. This paper reviews knowledge on GHB and 
derivatives, and explores the largest series of deaths associated with their non-medical use. Descriptive 
analyses of cases associated with GHB/GBL and 1,4 butanediol (1,4-BD) use extracted from the UK’s
National Programme on Substance Abuse Deaths database. From 1995 to September 2013, 159 
GHB/GBL-associated fatalities were reported. Typical victims: White (92%), young (mean age 32 years); 
male (82%); with a drug misuse history (70%). Most deaths (79%) were accidental or related to drug use,
the remainder (potential) suicides. GHB/GBL alone was implicated in 37%; alcohol 14%; other drugs 28%; 
other drugs and alcohol 15%. Its endogenous nature and rapid elimination limit toxicological detection. 
Post-mortem blood levels: mean 482 (range 0 - 6500; S.D. 758) mg/L. Results suggest significant caution 
is needed when ingesting GHB/GBL, particularly with alcohol, benzodiazepines, opiates, stimulants, and 
ketamine. More awareness is needed about risks associated with consumption.
Key words = GHB, GBL, Fatalities, Deaths, Toxicity, United Kingdom (UK)
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Abbreviations
1,4-BD 1,4 butanediol
AM Ante Mortem
AMCD Advisory Council on the Misuse of Drugs
BNF British National Formulary
BZP Benzylpiperazine
Carboxy-THC 11-nor-9-carboxy-delta-9-THC
CNS Central Nervous System
CPP 1-(3-Chlorophenyl)piperazine hydrochloride
DEA Drugs Enforcement Administration
EMCDDA European Monitoring Centre for Drugs & Drug Addiction
EMEA European Medicines Agency
GBL Gamma butyrolactone
GHB Gammahydroxybutyrate
GHV Gamma hydroxy valerate
GVC Gamma-hydroxy valeric acid; 4-methyl-GHB; Gamma-methyl-GHB
GVL Gamma-valerolactone
MDA Methylenedioxyamphetamine
MDMA Methylenedioxymethylamphetamine
MDPV Methylenedioxypyrovalerone
NMP N-Methyl-2-pyrrolidone
NPSAD National Programme on Substance Abuse Deaths
ONDCP Office of National Drug Control Policy
ONS Office for National Statistics
PM Post-mortem
TFMPP 3-Trifluoromethylphenylpiperazine monohydrochloride
THCC 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid
TIAFT The International Association of Forensic Toxicologists
1. Introduction
Gamma hydroxybutyrate, (GHB) is an endogenous chemical found in the human body. The protonated 
form is gammahydroxybutyric acid, whereas the deprotonated form of the carboxylic acid moiety is 
gammahydroxybutyrate (EMCDDA, 2002:11). GHB is also known as sodium oxybate, sodium 4-
hydroxybutyrate, and 4-Hydroxy-n-butyric acid. It can also be easily synthesised from readily obtainable 
ingredients. GHB’s prodrugs gammabutyrolactone (GBL; dihydrofuran-2(3H)-one) and 1,4 butanediol (1,4-
BD; BDO) are easily converted into GHB in the body (WHO, 2001).
The misuse of GHB and these prodrugs increased greatly in Western countries from the early 1990s, 
especially in the club and dance scenes (EMCDDA, 2002; Kelly et al., 2006). The period since has been 
marked by claims that the substances have been implicated in a rising number of deaths in the USA, 
Western Europe, Australasia, and other developed countries (Caldicott et al., 2004; EMCDDA, 2008; 
Zvosec et al., 2011).  
The aim of this paper is two-fold: (a) to provide an update on the present state of knowledge of GHB/GBL 
and (b) to make publicly available detailed particulars of fatalities associated with GHB, GBL and 1,4-BD 
that have been identified in the United Kingdom (UK). Section 2 gives an overview of the following topics: 
chemistry and pharmacology; metabolism and pharmacokinetics; medical uses; legal status; addiction 
potential; non-medical uses; recreational use in the UK; availability; route of administration and usage;
effects; hospital presentations; and fatalities. Section 3 looks at UK fatalities in depth, especially: methods 
and sources of data; detailed analysis of UK data; and a discussion of these data in relation to the wider 
literature. The latter includes reflections on: socio-demographics; post-mortem toxicology; pre-existing 
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medical conditions; drug effects and mental health issues; and drug interactions. The paper highlights the 
risks associated with the consumption of GHB and derivatives, especially with regard to recreational use. 
It also contributes to the pool of knowledge being built up on these drugs.  
2. Overview of the literature on GHB/GBL
2.1 Chemistry and pharmacology
GHB is a natural substance found in the human central nervous system and in other organs such as the 
liver, kidney, heart, bones as well as brown fat (Nelson et al., 1981). The greatest concentration in 
humans is found in the basal ganglia of the brain, with binding sites in the same location as well as the 
cortex, hippocampus, mid-brain and substantia nigra (Jones, 2001). Some research suggests that there 
are alternative sources of GHB, which may play a very significant role in GHB production (Feigenbaum 
and Howard, 1996; Snead et al., 1982), especially in the periphery, since GHB levels there are 
comparatively high yet peripheral levels of GABA are very low to absent. Its primary endogenous 
precursor is the neurotransmitter GABA which is converted enzymatically to succinic semialdehyde by 
mitochondrial GABA transaminase; succinic semialdehyde is then reduced to GHB by cytosolic 
semialdeyde reductase. It eventually enters the Krebs cycle, the main metabolic pathway in aerobic 
organisms, (Maitre, 1997). Β-oxidation is also a possible elimination route (Keating, 2014; Snead and 
Gibson, 2005).
Similar to the neurotransmitter gamma-aminobutyric acid (GABA), it possesses distinct excitatory 
properties (in addition to its sedative and anaesthetic effects) which may be due to its effect on the 
mesolimbic dopaminergic system (WHO, 2001). Some observations seem to support the hypothesis that 
GHB is a neurotransmitter with its own receptor system (Absalom et al., 2012; Maitre, 1997; Nava et al., 
2001). In the brain GHB is synthesised from GABA in cells containing glutamic acid decarboxylase, the 
marker of GABA-ergic neurons. It is accumulated by the vesicular inhibitory aminoacid transporter (VIAAT) 
and released by depolarisation via a Ca2+ dependent-mechanism. GHB can be metabolised in vivo to 
gamma-aminobutyric acid (GABA) and trans-4-hydroxycrotonic acid (T-HCA); the first being
pharmacologically active at GABAB receptors (Quang et al., 2002a) and the second one binding to the 
GHB receptor with 4-fold higher affinity than GHB itself (Wellendorph et al., 2005). A family of GHB 
receptors exists in the brain which possesses hyperpolarising properties through Ca2+ and K+ channels. 
These receptors are thought to regulate GABA-ergic activities via a subtle balance between 
sensitised/desensitised states. According to Maitre et al. (2005), absorption of large amounts of GHB 
desensitises GHB receptors. This modification, along with direct stimulation of GABAB receptors by the 
molecule, creates a disturbance, in several brain areas, of GABA, dopamine and opiate release. They
suggest this adaptation phenomenon is probably responsible for the therapeutic and recreational effects 
of exogenous GHB.  The activation of GABAA and GABAB receptors induced by GHB’s conversion to 
GABA might be responsible for GHB’s anxiolytic and sedative effects (Skala et al., 2014). GHB can be 
converted to GABA at high concentrations, as would be attained during recreational abuse or in vivo study 
of an administered drug (Collier and De Feudis, 1970; Hechler et al., 1997; Vayer et al., 1985).
Experimental data suggest that GHB has alcohol-mimetic effects at low dosages (e.g. 50mg/kg/day) 
facilitating the suppression of alcohol cravings (Skala et al., 2014). 
GHB can also be synthesised in vivo from its prodrugs or precursors GBL and 1,4-BD, with GHB being the 
compound exerting the pharmacological effect (Carai et al., 2002; Guidotti and Ballotti, 1970; Roth et al., 
1966; Poldrugo and Snead, 1984; Quang et al., 2002a, 2002b; Schneidereit et al., 2000; Snead, 1982; 
Snead et al., 1989; ). 1,4 Butanediol, a naturally occurring aliphatic alcohol, has been demonstrated to 
serve as a source of GHB (Poldrugo and Snead, 1984). GBL, a naturally occurring lactone precursor, is 
readily and irreversibly metabolised to GHB by peripheral lactonases (Roth and Giarman, 1968).
2.2 Metabolism and pharmacokinetics
Following exogenous (oral) administration, GHB is rapidly absorbed from the gastro-intestinal tract. Single 
oral doses of 12.5, 25, and 50 mg/kg reached peak plasma concentrations in 25 (range 20-30), 30 (range 
20-45), and 45 (range 30-60) min respectively (Palatini et al., 1993).  This is in line with effects starting 15 
min after an oral dose (Galloway et al., 1997). The elimination half-life of GHB is 27 min, and proceeds in 
a dose-dependent saturable manner (Palatini et al., 1993). Only 2-5% of GHB is eliminated unchanged in 
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urine (Hoes et al., 1980; Laborit, 1964). The dosage-response curve for GHB is steep. Time to peak 
concentration of 1,4-BD is 25 min (Thai et al., 2007).
The distribution throughout the body is fast and follows a two-compartment model (Brenneisen et al., 
2004). The apparent distribution volume is reported to be 0.19 to 0.4 L/kg (Baselt, 2008; Borgen et al., 
2003), and is not significantly affected by gender, food, or liver cirrhosis (Borgen et al., 2003; Ferrara et 
al., 1996). The pathway of GHB production after death remains unclear and it has also been suggested 
that GHB can be a product of post-mortem decomposition (Fieler, Coleman and Baselt, 1998; Sakurada et 
al., 2002).
GBL is metabolised quickly to GHB by peripheral calcium dependent serum lactonases or by 
nonenzymatic hydrolysis (Arena and Fung, 1980; Roth and Giarman, 1965; Roth et al., 1967); the half-life 
of this conversion being estimated as < 1 min (Roth and Giarman, 1966). Time to peak serum 
concentration of GBL is 36-57 min, with an elimination half-life of 30-52 min (Meyer et al., 2014). Studies 
of patients suffering from a rare inborn error of metabolism (4-hydroxybutyric aciduria) were found to have 
very high concentrations of GHB in the urine (typically greater than 200 mg/L), plasma and cerebrospinal 
fluid (CSF) (Divry et al., 1983; Rahbeeni et al., 1994). GBL has greater lipid solubility than GHB, allowing it 
a more uniform absorption. Its greater lipophilicity may also result in its absorption into a variety of tissues 
which possibly act as reservoirs lengthening the duration of GBL action (Lettieri and Fung, 1978). It is 
regarded as more potent than GHB because of its more rapid absorption and greater bioavailability, 
although its effects are not as long-lasting (Brunt et al., 2014).
By contrast, the slower elimination of 1,4-BD, the diol alcohol (dihydroxy) precursor of GHB, suggests its 
effects last longer than those of GHB (Brunt et al., 2014). 1,4-BD undergoes two-stage conversion in the 
liver in vivo via enzymatic biotransformation to gamma-hydroxy butyraldehyde by alcohol dehydrogenase 
(ADH) and then aldehyde dehydrogenase to GHB (Bessman and Fishbein, 1963; Poldrugo and Snead, 
1986; Snead et al., 1989; Quang et al., 2002a, 2002b; Wang, 2007). There is great inter-individual 
variation in the speed of metabolism of 1,4-BD to GHB; this may be associated with ADH-IB and G143A 
polymorphism (Thai et al., 2007). The elimination half-life of 1,4-BD is 39 ± 11 min; time to maximal GHB 
concentration being also 39 ± 11 min (Thai et al., 2007). The sedative/hypnotic effect of 1,4-butanediol is 
mediated by its conversion in vivo into GHB which, in turn, binds to GABAB receptors (Carai et al., 2002). 
The common metabolic pathway of 1,4-BD and ethanol leads to potential interactions between them 
(Poldrugo and Snead, 1984, 1986). There is a synergistic effect between ethanol and 1,4-BD (McCabe et 
al., 1971; Poldrugo et al., 1985), and between ethanol and GHB in respect of synergistic sedative effects 
(McCabe et al., 1971; Van Sassenbroeck et al., 2003a). 
The pharmacokinetics of GBL and 1,4-BD, including their initial distribution and rate of conversion to GHB, 
may influence their pharmacological actions. Hence, GBL and 1,4-BD may not display actions identical to 
GHB nor to each other. Early studies of these agents support non-identical time courses of action, 
suggestive of differences in their pharmacokinetics seen in mice; however, stimulatory effects are more 
pronounced for 1,4-BD than for GBL (Fiebre et al., 2004). The hypothermia produced by GBL is more 
pronounced than that produced by 1,4-BD (Fiebre et al., 2004).  These data, conducted with a limited 
number of non-equivalent doses of these drugs, suggest that GBL and 1,4-BD may have differential 
effects. These different effects, whether pharmacodynamic or pharmacokinetic, may contribute to the 
abuse potential and/or pharmacological or toxicological actions of each agent (de Fiebre et al., 2004), as 
well as different overdose risks (Brunt et al., 2014). 
2.3 Medical uses of GHB  
GHB decreases the oxygenation needs of tissues and protects cells during states of hypoxia. For these 
reasons it has been suggested to have some potential for use in emergency treatment, especially for 
haemorrhagic and septic shock (Jones, 2001). When exogenously administered, GHB is rapidly absorbed. 
It crosses the blood–brain barrier with relative ease, penetrates into the brain, and exerts a number of 
psychopharmacological effects. Acute effects include euphoria, ataxia, confusion, hallucinations, 
anxiolysis, amnesia, sedation/hypnosis, loss of consciousness, and anaesthesia (Laborit, 1964; Maitre, 
1997; Shannon and Quang, 2000; Snead and Gibson, 2005; Teter and Guthrie, 2001). In animals, this 
drug causes alterations in locomotor activity (Cook et al., 2002; Davies, 1978), loss of the righting
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response (Dudek and Fanelli, 1980), seizures (Snead, 1990) and hyper/hypothermia (Kaufman et al., 
1990).
In 1960 Dr Henri Laborit synthesised GHB while trying to produce a GABA analogue or precursor 
capable of easily crossing the blood-brain barrier (Laborit et al., 1960a, 1960b). GHB was initially used as 
an anaesthetic (Vickers, 1969). However, it remained undeveloped for this use because of the high 
incidence of adverse effects, especially vomiting and seizures, during early clinical trials (Wood et al., 
2011). In the mid-1990s GHB’s role underwent re-evaluation in the emergency and critical care fields, 
especially long-term sedation, due to its rapid metabolism and reliable induction of sedation/anaesthetic 
without depression of cardio-circulatory or respiratory measures, kidney and other functions (EMCDDA, 
2002).
GHB is a medicinal product by definition of Article 1 of EC Directive 2001/83/EC5 and in the UK is 
controlled by the Medicines Act 1968 and associated regulations. In the UK, it is an unlicensed medicinal 
product and can only be sold or supplied to the public by a doctor or dispensed by a pharmacist in 
response to a prescription written by a doctor. GHB is not manufactured legally in the UK. The British 
National Formulary (BNF) lists Xyrem® as a hypnotic for use in treating narcolepsy with cataplexy (under 
specialist supervision). It is supplied as an oral solution of 500mg/mL (BNF, 2014).
In only five EU Member States is GHB a licensed medicine for human use; it is not authorised for 
veterinary use. GHB is used in France and Germany (Andresen et al., 2010) as a surgical anaesthetic 
(Gamma OH™ and Somsanit™ respectively), and in Austria and Italy (Alcover®) to treat alcohol 
withdrawal symptoms (Gallimberti et al., 1989). In Italy it has been tested to treat opiate addiction as well
(Gallimberti et al., 1993; Maremmani and Pacini, 2007). GHB was licensed in Europe in 2005 (EMEA, 
2007) for use in the treatment of narcolepsy (a rare sleep disorder characterised by excessive daytime 
sleepiness and presence of irresistible daily attacks of refreshing sleep) and cataplexy in narcoleptic 
patients (Gallimberti et al., 1994; Mamelak et al., 1986). It is also approved for treating narcolepsy in 
Canada, Switzerland and the USA (Skala et al., 2014).  In 2002, the US FDA gave approval for Xyrem® 
(with GHB as an active ingredient) to be used in the treatment of cataplexy attacks in patients with 
narcolepsy (ONDCP, 2002). It is available in the Netherlands for this purpose (van Amsterdam et al., 
2012). It has been suggested for the treatment of fibromyalgia (Maitre et al., 2005).
2.4 Legal status of GHB, GBL and 1,4-BD
In the USA GHB was classified as a DEA-listed Schedule 1 drug on 18 February 2000, and thus is not 
licensed for use in medical treatment. On the advice of the World Health Organisation, the United Nations 
Commission on Narcotic Drugs added GHB to Schedule IV of the 1971 UN Convention on Psychotropic 
Substances on 29 March 2001. The EU agreed in the same month that individual Member States should 
closely monitor GHB and also decided that the UN decision should be implemented by incorporation into 
domestic legislation as Member States saw fit (EMCDDA, 2001). GHB is now controlled in at least 22 
Member States and Norway, as well as Chile. GHB is regulated in Hong Kong as a prescription medicine. 
GBL and 1,4-BD are controlled in Bulgaria, Italy, Latvia, Norway and Sweden under identical or similar 
legislation to that relating to GHB (Andresen et al., 2010). GBL is controlled in Austria, Canada, Israel, 
Romania, Russia and the USA. GHB, GBL and 1,4-BD are controlled in Australia and New Zealand as 
Class B drugs, i.e. having a ‘high’ risk of harm. Action was also taken against GHB in Switzerland in 2001.
GBL is controlled as a precursor in Turkey, and 1,4-BD similarly in Canada. 
On 1 July 2003 GHB became controlled in the UK under the Misuse of Drugs Act 1971 as a Class C drug. 
This means that anyone possessing the drug can face two years in prison, while suppliers can expect a 
jail term of up to five years.  GHB also became a substance listed under Schedule 4 Part I of the Misuse 
of Drugs Regulations 2001. The legislation makes it an offence to manufacture, supply, import, export and 
possess GHB without lawful authority. GBL and 1,4-BD became Class C drugs under Schedule 2 from 23 
December 2009 where they are intended for human consumption. 
2.5 Addiction potential  
Tolerance develops to GHB/precursor effects in rodents (Colombo et al., 1995a; Gianutsos and Moore, 
1978; Itzhak and Ali, 2002). Abanades et al. (2007) suggest that GHB is both physically and 
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psychologically addictive, and has a high abuse potential, appearing to cause physical dependence 
(EMCDDA, 2002; Galloway et al., 1997). Data from a study of primates indicate that chronic 1,4-BD 
administration produces physical dependence (Goodwin et al., 2013). Cross-tolerance may exist between 
GHB and alcohol in humans (EMCDDA, 2008), as it does in animal models (Colombo et al., 1995b; Fadda 
et al., 1983).
Those developing dependency are likely to have been using these substances for several months, several 
times a day (McDonough et al., 2004; Wojtowicz et al., 2008). However, there is little evidence of abuse 
amongst those patients using GHB for narcolepsy (Brunt et al., 2014), when taken at the recommended 
dosage. A study of 26,000 narcolepsy patients treated with sodium oxybate found that adverse effects 
included: abuse (0.0390%); dependence (0.0016%); withdrawal symptoms (0.0310%); overdose with 
suicidal intent (0.0031%); and death (0.0800%) (Wang et al., 2009). Between 2.6% and 10.1% of patients 
with alcohol dependence treated with sodium oxybate developed craving for the drug and increased their 
dose to 6-7 times the recommended one (Beghè and Carpanini, 2000). The likelihood of craving is highly 
elevated for such patients who also have a psychiatric condition (Caputo et al., 2011). Those with a 
previous history of opioid or cocaine dependence are also at such risk (Caputo et al., 2009). 
In rare cases, withdrawal symptoms might be observed following withdrawal from sodium oxybate (EMEA, 
2007, 2014). Withdrawal syndrome (characterised by insomnia, muscular cramping, tremors and anxiety) 
has been reported in some patients following cessation of long-term administration of high doses of GHB 
(Galloway et al, 1994; LeTourneau et al., 2008), GBL/GHB (Durgahee et al., 2014), and GBL and 1,4-BD 
(Catalano et al., 2001; Dyer et al., 2001; Evans and Sayal, 2012; Zvosec et al., 2011), similar to those 
seen in respect of withdrawal from alcohol and benzodiazepines (Le Tourneau et al., 2008). The 
symptoms appear within a few fours of the last dose taken, becoming severe by 24 h (Wood et al., 2011). 
There is a risk of delirium, hallucinations and/or acute psychosis if left untreated (Skala et al., 2014).
Cases of GBL withdrawal have been successfully treated through the use of clonazepam/lorazepam in 
conjunction with haloperidol (Meyer et al., 2014a, 2014b; Sewell et al., 2015).
2.6 Non-medical uses of GHB and its precursors 
GHB was first sold as a dietary supplement, and by the late 1980s was marketed in the US as a steroid 
replacement for body-builders and weight lifters. It has been shown to stimulate the release of human 
growth hormone, which could increase muscular mass (Sivilotti et al., 2001; Takahara et al., 1977). 
Growth hormone release from the anterior pituitary occurs during slow wave sleep which is increased by 
GHB (Bluet-Pajot et al., 1978; Gerra et al., 1994; Mamelak, 1997; Takahara et al., 1977;). However, there 
is no clear evidence that the short-term elevations in growth hormone produced by GHB result in any 
increase in muscle mass (Vayer et al., 1987). Despite this, GHB has been widely used among the body-
building community and is believed by some to have been the primary focus of GHB misuse in the mid-
1990s in the USA (Friedman et al., 1996) and Sweden (EMCDDA, 2002). GHB’s ability to decrease body 
fat makes its use attractive as a means of weight loss (Chin et al., 1992; Friedman et al., 1996; Luby et al., 
1992; Vayer et al., 1987). GHB has also been used as an appetite suppressant (EMCDDA, 2002).
GHB has been promoted as an aphrodisiac in both heterosexual and homosexual markets (Romanelli et 
al., 2003). It is used particularly in the latter population because of its energy boost and increase in libido 
(Palamar and Halkitis, 2006), as well as to relax (muscles) and give more confidence (Bourne et al., 
2014), as well as to facilitate sex-work and ‘chem-sex’ (Durgahee et al., 2014). GHB, GBL and similar 
substances have also been linked to cases of so-called 'date-rape' reported by the media, both in the 
USA, Europe (Andresen et al., 2010; Németh et al., 2010) and the UK, including a recent case where 
GHB/GBL was administered with the Novel Psychoactive Substance DOC (2,5-Dimethoxy-4-
chloroamphetamine) (Bennett, 2014); inaccurately in some instances (EMCDDA, 2008; Hagemann et al., 
2013; Sturman, 2000). More recently, the industrial solvent NMP (N-Methyl-2-pyrrolidone) or more 
accurately its metabolites have been identified in cases of sexual assault in Europe (DPA, 2013). NMP is 
sometimes used as a substitute for GBL (Reisch, 2008), and has been found in some GHB solutions 
(DEA, 2004). Also of interest is that a related substance GVL (gamma-valerolactone) is being used 
recreationally in Europe; it has similar effects to GHB and its pro-drugs, and is metabolised by a lactonase 
to GVC (gamma-hydroxy valeric acid, 4-methyl-GHB, gamma-methyl-GHB) (Carter et al., 2005).  It is a 
legal substance but has a two-fold lower affinity for the GHB receptor (Andresen-Streichert et al., 2013).
Higher doses of GHV (Gamma hydroxy valerate) are needed to achieve similar results to GHB, thereby 
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increasing the risk of poisoning and death. It is used recreationally in a similar way to GHB, e.g. by mixing 
with water or alcohol (Erowid, 2004).
The more recent primary mode of GHB abuse worldwide has been for its subjective (empathogenic), 
hypnotic, euphoric, disinhibitive and potentially hallucinogenic effects (ReDNet, 2012). Illicit GHB/GBL 
users describe their subjective effects as comparable to alcohol (Colombo et al., 1995a), MDMA/ ‘ecstasy’ 
(Galloway et al., 2000), and flunitrazepam (Abanades et al., 2007). Drug workers and some user fora 
comments suggest that GHB may be used as a substitute for alcohol or other drugs to get intoxicated so 
as to avoid detection by testing in situations such as treatment compliance, driving and the workplace
(EMCDDA, 2002). It does not react with the reagents in the commonly used field test-kits. At the same 
time it provides a cheap alternative to such substances (EMCDDA, 2002).
GHB and its prodrugs are often used recreationally with other substances (Erowid, 2013b, 2013c), 
including alcohol, cannabis, and stimulants (ecstasy, cocaine, amphetamines) (Durgahee et al., 2014; 
Korf et al., 2002; Miotto et al., 2001; Sumnall et al., 2008). Many GHB users employ MDMA to extend its 
effects (Kim et al., 2007; Korf et al., 2002).  It causes the extracellular concentrations of key 
neurotransmitters to increase, e.g. 5HT is a principal element providing ecstasy’s sought-for effects, but 
dopamine and noradrenaline have stimulant effects. GHB is taken to moderate the latter’s effects, 
especially the almost re-experiencing of MDMA hit and delaying the come-down (Uys and Niesink, 2005). 
GHB and its derivatives are more likely to be used in private settings rather than in public night life 
settings (67% vs. 26% respectively; Sumnall et al., 2008). A similar pattern is noted in Australia (Sindicich 
and Burns, 2013). A shift in GHB use from dance venues and events to private homes and parties was 
noted in Australia between 2001 and 2007 (Dunn et al., 2009). Settings for use appear to influence 
adverse effects, being more negative in club rather than domestic settings (Sumnall et al., 2008). 
2.7 Recreational use in the UK
For much of the period up to the end of 1990s, there is little, if any, reliable information on the recreational 
use of GHB in the UK. However, there are some sources that can throw some light on the topic, especially 
those that cover specific drug user subcultures. 
The intoxicating and euphoric effects of GHB were discovered by recreational users and first appeared on 
the UK dance and club scenes during the spring of 1994, initially in 'gay' circles before spreading to other 
populations. Combined results from Independent Drug Monitoring Unit (IDMU) surveys conducted 
between 1999 and 2002 of GHB/GBL users found that very few respondents had used those substances 
before 1994 and even fewer prior to 1990 (Atha and Davis, 2003). GHB became increasingly popular in 
dance and club circles during the 2000s, as well as GBL and 1,4-BD several years later. 
Self-selecting respondents to the UK Mixmag magazine’s survey (initially postal and more recently online) 
of individuals predominantly in their early twenties found that lifetime use of GHB was 12.8% in 1999, 
15.9% in 2000, 14.1% in 2001, 12.8% in 2002, and 17.5% in 2003. Mean age at first use during this 
period varied between 21.4 and 24.5 years. Current i.e. last month use was 3.4% in 1999, 4.0% in 2000, 
2.7% in 2001, 3.9% in 2002 and 3.1% in 2003 (McCambridge et al., 2007; Mixmag 2002, Winstock, 2001).
A decade later, the online 2009 Mixmag survey and subsequent Global Drug Survey showed that 15.2% 
had ever tried GHB compared to 5.8% for GBL. Last month use levels were similar (1.7% and 1.6% 
respectively; Dick and Torrance, 2010). Lifetime use of GHB and GBL in 2010 was 11.8% and 5.8%, with 
last year (i.e. 12 months prior to the survey) use rates at 2.5% and 2.4% (Mixmag, 2011). The 2011/12 
survey (n = 7,700) revealed that 7.7% of UK respondents had ever tried GBL compared to 3.8% for GHB;
the proportions for last year use were 1.6% and 1.5% respectively, and for regular clubbers 2.5% and 
2.0% (Mixmag, 2012; Winstock, 2012). The 2012/13 survey reported that respondents scored GHB 6.8 
out of 10 for “value for money” (Winstock, 2013); this rating fell to 6.4 for GHB/GBL in 2014 (Winstock, 
2014).
Surveys in 1999 and 2000 by IDMU also revealed that less than 3% of those interviewed at pop festivals 
and similar large events had ever used GHB (Atha and Davis, 2001).  Both the IDMU and Mixmag surveys 
report that most users had tried many other drugs before experimenting with GHB. The peak age of 
initiation in the IDMU surveys was 17 or 18 years, with another peak at around 25 years (Atha and Davis, 
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2001). These findings are not inconsistent with the Mixmag results as the latter captures a different, 
typically older, age group. IDMU suggest that the relatively widespread of initiation ages is in line with the 
fairly recent arrival of recreational GHB usage (at the time of the surveys), and that those taking the drugs 
are not naïve users (Atha and Davis, 2003; Sumnall et al., 2008; Wood et al., 2009).
A survey (n = 308) by Measham et al. (2011) conducted in “gay friendly” dance clubs in south London in 
July 2010 found that GHB and GBL were used relatively more often than in other types of venue. Lifetime 
use of these substances was 34% and 27%, with last year use being 22% and 24% respectively. This, 
perhaps, indicates a move towards GBL from GHB. This was underlined by a higher proportion having 
used or planning to use it at the time of interview. These patterns are echoed in a survey of attendees at 
genito-urinary clinics in July-September 2011 conducted in London which found higher rates of lifetime 
and last month use of both GHB and GBL by gay men than in heterosexual males. Lifetime use of GHB 
and GBL amongst gay men was 22.7% and 16.1% respectively; last month rates were 2.4% and 3.1% 
(Hunter et al., 2014). Lifetime use of GHB/GBL amongst gay males in the south London boroughs of 
Lambeth, Southwark and Lewisham between August 2013 and March 2014 was 30.6%, with 20.1% using 
in the previous year and 10.5% in the previous 4 weeks (Bourne et al., 2014). The latter rate of 10.5% for 
previous month use contrasts with 5.5%  (Odds Ratio (OR) 2.00, 1.58-2.53) elsewhere in London and 
1.6% elsewhere in England (OR 6.94, 5.38-8.97; Bourne et al., 2014). The highest level of previous month 
use was amongst 30-39 year olds. A survey of Lancashire nightclubs (n = 343) in spring 2012 found that 
lifetime use of GHB/GBL was 4% with last year use at 1%; lifetime use had been 6% in autumn 2010 
(Measham et al., 2012).  
The 2011 sweep of the ESPAD survey (European School Survey Project on Alcohol and Other Drugs) of 
students aged 15-16 years found that 1% of boys and girls in the UK had ever used GHB; the same as the 
wider survey average. By comparison, the 2003 and 2007 sweeps found that the rate in 2003 was given 
as 0% and 1% in 2007 (Hibell et al., 2004, 2009, 2012).
The Crime Survey for England and Wales (formerly the British Crime Survey), which monitors drug use in 
a general household survey of adults aged 16-59 years, only asked about GHB use in 2010/11 and 
2011/12 (Home Office, 2012). Last year use amongst this age-group was 0.0% in 2010/11 and 0.1% in 
2011/12. These low rates illustrate the difficulties that such surveys have in capturing drug use amongst 
difficult to access groups. Unfortunately, no other information is presented for GHB. 
Analyses of liquid samples in UK nightclub ‘amnesty’ bins appears to confirm a move from GHB to GBL in 
the years following the former’s control (Wood et al., 2008). A similar trend was reported in France in 
respect of 1,4-BD (EMCDDA, 2002). 
Limited data are available on the extent of GHB/GBL dependence in the UK. However, unpublished 
information from the National Drug Treatment Monitoring System (NDTMS) for England during the period 
2005/6 to 2013/4 indicates that for those under 18 years of age presenting for treatment with a primary 
dependence on GHB the number has not exceeded more than about 5 cases per year. However, the 
number of adults presenting rose from 10 in 2005/6 to 50 in 2007/8 to 2008/9, and then to 100 in 2010/1 
and 150 in 2011/2, but falling back to 130 in 2013/4 (personal communications to lead author from 
NDTMS, 16 January and 25 February 2015).   
2.8 Availability
GHB usually exists as either the free acid or as the sodium base (sodium oxybate). It is soluble in water 
and methanol. It is usually sold as a clear, odourless, salty-tasting liquid but can be found in powder or 
tablet form, and occasionally as a bright blue liquid (‘blue nitro’). The diversion of prescribed sodium 
oxybate appears to be very low; 0.00009% in the period 2002-8 in 15 countries worldwide (Wang et al., 
2009). GHB is usually obtained from friends and known dealers (Brunt et al., 2014; Sindicich and Burns, 
2013). Sharing GHB/GBL between not only friends and partners but also relative strangers in some 
settings (parties, clubs and saunas) is common in the male gay community (Bourne et al., 2014). Retailers 
are easy to find on the Internet, together with recipes for making it (EMCDDA, 2002, 2008; Sanguineti et 
al., 1997). Individuals also manufacture GHB themselves being able to easily obtain precursors (Brunt et 
al., 2014). 
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UK authorities took a range of actions to reduce supply and demand of GHB following increasing concern 
about its abuse and adverse effects. The Medicines Control Agency (MCA) undertook proactive 
enforcement activities in 1999-2000 involving retail premises in the Soho area of London. The Committee 
of Advertising Practice, together with the MCA, released an advertising alert to its members reminding the 
media that it is illegal to advertise GHB. The MCA set up a special unit to tackle internet advertising and 
supply and importation. Between 1995 and 2000 there were 23 charges brought under the Medicines Act 
1968, 10 of which were successful (Hansard, 2000).
The disruption of overt supply in retail outlets, including sex-shops, and catalogue sales led to patterns of 
distribution similar to those of illicit drugs (EMCDDA, 2002). The availability and use of 1,4-BD appears 
limited (ACMD, 2008). Although the apparent availability in terms of internet retailers has diminished, at 
the time of writing (February 2015) sites are offering 500ml of GBL cleaner for as low as €55 (Polish site: 
www.gbl.com), or up to 50L for US$1475 (Chinese site: www.yunxiangchem.com). 1,4-BD is on offer; 
100ml is US$50 with 16L available for US$1428 (an apparent US site: www.rightpricechemicals.com).
The IDMU 2002 survey suggested a bottle of GHB (typically containing 62.5ml) then cost £19.50 (€27) 
(Atha and Davis, 2003). £15 will purchase 30ml, while 1L of ‘GBL cleaner’ retails at about £80 (ReDNet, 
2012). In early 2006, 2ml of GBL was retailing in Austrian clubs for €10. In Finland, 50 ml of GHB costs 
€5-6 (Boyd et al., 2012). In the USA a ‘swig’ or capful retails in bars and at ‘raves’ for US$5-25 (DEA, 
2012). The price per ml in Australia in 2012 ranged from Australian $ 3 to 9 (Sindicich and Burns, 2013).
There have been very few convictions or cautions in England and Wales for production, possession with 
intent to supply, or supplying GHB. However, the number of offenders dealt with in this way rose from zero
in 2002 to 20 in 2011 but fell to 6 in 2013 (personal communication from the Ministry of Justice to JC, 10
August 2014, 582-14 FOI 92136 Reply). The increased use of GHB/GBL amongst the male gay 
community in south London, and more generally, has been attributed by Bourne et al. (2014) to “the rising 
cost, poor quality and reduced availability of ecstasy and cocaine”.
Before control in 2003, GHB itself was available for purchase from premises in the Soho district of London 
and in many clubs and pubs. In dance settings at the beginning of the century GHB was often sold in 3ml 
plastic bottles, containing about 3g, being offered for social use for relaxation, mild euphoria or post-party 
for sleep.  Many illicit forms of GHB are available under a range of names, including: sodium oxybate, 
sodium 4-hydroxybutyrate, Grievous Bodily Harm (GBH), Liquid Ecstasy, "Georgia Home Boy", "Juice", 
"Liquid Ecstasy", "Mils", "G", "Liquid X", and "Liquid G", as well as "Fantasy”. The precursors 
gammabutyrolactone - GBL - (also known as by such names as Renewtrient and Blue Nitro), and 1,4-
butanediol (BDO) (also known as Serenity, Enliven, Somato Pro), are used in the chemical industry, and 
in some cleaning and cosmetic products. In excess of 200,000 tons of GBL is produced globally each 
year, principally in China, Germany, India and the USA (Pazos et al., 2013).  It is rarely controlled under 
national legislation as it is a commonly used industrial solvent. Internet sites offering supply and 
distribution of GBL are mainly (60%) based in the Netherlands, but also Poland and the UK. Pazos et al. 
(2013) identified 39 sites selling GBL in 2010/1. Some nail varnish remover pads and solutions contain 
GBL, and have become a source for recreational use (EMCDDA, 2002). The Internet provides easy 
access to instructions on how to synthesise GBL and 1,4-BD as well as the materials to do so. These pro-
drugs are mainly seized in liquid form (EMCDDA, 2002).  It is also worth noting that Xyrem® is also 
available without prescription from sites posing as legitimate online pharmacies. For example, one site 
(drugstrading.biz), apparently based in Pakistan (based on the telephone number for queries), offers
500mg/ml vials for US$4 for a minimum order of 20 vials.
Information on seizures of GHB and its prodrugs are not given in the statistics published by the Scottish 
and Northern Ireland authorities. However, the most recent Home Office figures show that the number of 
GHB seizures by police forces in England and Wales and the UK Border Agency (formerly Customs) rose 
from 29 in 2003 (when it became controlled) to 66 in 2010/11 before falling to 45 in 2011/12 but increasing 
to 61 in 2012/3, but falling back to 41 in 2013/4 (Dhani, 2014). The quantity seized has not exceeded 10kg 
in any year apart from 2003 (40kg), varying from year to year (Coleman, 2013; Dhani, 2014). 
2.9 Route of administration and usage
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Although GHB is available as a salt or powder form, Wood et al. reported in 2011 that there had been no 
reports up till then of nasal insufflation. However, there are occasional reports of such use (Barker et al., 
2007). Typically, it and its analogues are used orally, although there are occasional reports of intravenous 
(IV) use (EMCDDA, 2002), of “shelving” (insertion into the vagina), and of “shafting” (insertion into the 
rectum) (Sindicich and Burns, 2013). Powder is usually dissolved in water or other drinks prior to use 
(EMCDDA, 2002). Occasionally, capsules containing GHB’s salt (sodium oxybate) are used (Andresen et 
al., 2010).
The median quantity of GHB used was 3ml in a typical session and 4ml in a heavy session in a study by 
Sindicich and Burns (2013). Issues can also arise because of inter-person variability in effects (Kam and 
Yoong, 1998), the selection of the correct dosage or taking doses too close together (EMCDDA, 2002). 
Depending upon tolerance levels, recreational doses range from 1-5g daily, 15-70mg/kg for a 70kg adult 
(Friedman et al., 1996; Hodges and Everett, 1998). Durgahee et al. (2014) report mean daily usage of 
53ml (median 40, range 5-200) in a group (n = 27) of patients presenting to drug services in Brighton & 
Hove (UK) with primary GHB/GBL dependence during 2008-13, with ‘top ups’ at 1 hr (41%) or 2 hr (44%) 
intervals. Suggested dosages are: 0.5g for relaxation and disinhibition, 1g for euphoric effects, and 2-3g 
for deep sleep (Erowid, 2013a; Lycaeum, 1998; Ward et al., 1998). Typical recreational doses are 
reported to be 2.5g (EMCDDA, 2008). Variation in the GHB concentrations in such solutions, as well as 
pre-prepared ones, can give rise to some of the dangers associated with illicit use (Hodges and Everett, 
1998; van Rij et al., 2004; Williams, 1998). GHB 40ml (3 - 9 doses) could hold a dose of as little as 3g or a 
potentially toxic one of 20g (Thomas et al., 1997). Such variations in concentration mean an increased risk 
because of GHB’s narrow therapeutic window and steep dose-response association (van Amsterdam et 
al, 2012). The GBL dose range is typically 1-3ml, with user fora suggesting taking initial doses of 1.5-2ml 
with a follow-up dose of 1ml 30 to 60 mins later (drugs-forum, 2014). Suggested dosages are: “a good 
relaxing/mood enhancing” 0.5-1ml; “f**k you up” 1.5-2ml; and “knock you out” 3ml, based on a conversion 
rate of pure GBL 1ml = GHB 1.65g (drugs-forum 2014; bluelight, 2014; mindandmuscle, 2014).
2.10 Effects 
Early work on GHB as an anaesthetic demonstrated altered levels of consciousness associated with the 
following serum concentrations: (a) greater than 260 mg/L, patients were unresponsive to painful stimuli 
(comatose); (b) 156-260 mg/L, patients were asleep but responsive; (c) 52-156 mg/L, patients exhibited 
spontaneous movement with occasional eye opening; and (d) less than 52 mg/L, patients awoke (Helrich 
et al., 1964).
Clinical effects become evident about 5-20 minutes after ingestion (peaking after 30-60 mins (Mason and 
Kerns, 2002), and can last for up to 7 hours, depending on the dose. The duration of the effects is also 
influenced by combination with other substances ingested/taken at the same time (EMCDDA, 2002:13). 
Initial feelings after ingestion are euphoria and calmness, and then intoxication. A low to moderate oral 
dose of 10mg/kg (0.75g) can produce short-term amnesia and hypotonia, inhibitions are lowered and 
libido increased. A high dose of 20-30 mg/kg (1.5-2.5g) leads to drowsiness and sleep, and can cause 
nausea, vomiting, muscle stiffness, dizziness and confusion. Very high doses of 50-70 mg/kg (4-5g) lead 
to convulsions (Cagnin et al., 2011), amnesia, hypotonia, and coma; it may also cause bradycardia and 
cardiopulmonary depression is enhanced. Doses in excess of 70mg/kg (5g) can cause cardio-respiratory 
collapse (van Amsterdam et al., 2012; van Rij et al., 2004). A case of sodium oxybate-induced central 
sleep apnoea has been reported in a patient treated for narcolepsy and cataplexy with no previous history 
of apnoea (Frase et al., 2013).
However, it should be noted that these ranges are far from being absolutes. The same dose can have 
very varied effects on different individuals. The same individual may react differently to oral ingestion of 
GHB on various occasions (Teter and Guthrie, 2001). Variability in the effects of GHB and related 
substances also arises from the way in which their manufacture can cause differences in purity levels. 
Furthermore, the effects of GHB are exacerbated by use with alcohol and other drugs, especially 
benzodiazepines, opiates, etc. (EMCDDA, 2002). Combining a normal dose with alcohol can cause 
unrouseable sleep. Lamb et al. (2003) suggest that alcohol and GHB may not have a synergistic effect, 
but their combined effect is “less than additive”. Loss of consciousness for short periods during sex with 
GHB/GBL appears to be common and is considered “relatively normal” by males in the South London gay 
community (Bourne et al., 2014:59). 
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Additional symptoms such as aggression, hypothermia and tonic-clonic convulsions do not have a clear 
dose relationship (van Amsterdam et al., 2012). Galloway et al. (2000) suggest that a potentially lethal 
dose of GHB ranges from 15-50g (250-750mg/kg).
2.11 Hospital presentations
The true extent of acute undesired effects of GHB and its analogues is not known, especially since routine 
toxicological screening is not undertaken in most Emergency Departments (EDs) (EMCDDA, 2002). This 
is because the results are not available in an adequately timely fashion to inform treatment options (Wood 
et al., 2011). Furthermore, there appear to be many unconfirmed anecdotal instances of intoxications 
(Erowid, 2013a).
The growing recreational use of GHB during the 1990s led to increased numbers of admissions to 
European EDs (up to 200 by 2000, chiefly in Sweden, the UK, the Netherlands, Denmark, Belgium, 
Finland, Spain and Norway) and calls to poisons centres in the EU (EMCDDA, 2002; Galicia et al., 2011), 
and to ED admissions in the USA (ONDCP, 2002) and Australia (Dietze et al., 2008; EMCDDA, 2002). 
Between 2006 and 2010, the number of ED visits recorded by the US NEW DAWN monitoring system 
increased by 65% from 1084 to 1787 (DEA, 2012). Oslo saw an increase in the number of admissions due 
to GHB from 68 in 2003 to 96 in 2008; these accounted for 7% and 9% respectively of all admissions in 
those years (Rønning, 2013). Helsinki experienced a more than doubling in such incidents in 2006-7 
(Boyd et al., 2012). These patterns reflect the dangers inherent in its misuse. 
An analysis of ambulance attendances involving GHB in Melbourne, Australia found there were 618 
incidents in a 46 month period between March 2001 and October 2005, of which 362 involved the drug on 
its own (Dietze et al., 2008). Such attendances increased by an average of about 4% per month. Most 
patients were <25 years, females ranged from 35-40%, were attended in public places (78-85%), and had 
Glasgow Coma Scores <10. About 90% were taken to hospital.
One central London ED recorded 158 GHB/GBL presentations in 2006; there were no cases of 1,4-BD 
(Wood et al., 2008). Most presentations involved males aged 20-34, but it should be noted that this ED’s 
catchment area includes a “substantial” ‘gay’ club scene (Hunter et al., 2014). Only 34% reported having 
used GHB/GBL alone; other combinations included alcohol (34%), MDMA (32%), ketamine (22%), 
cocaine (14%), amphetamine (14%). One Edinburgh hospital reported an increase in admissions from 3 in 
2000 to 39 in 2006 (EMCDDA, 2008).
The UK National Poisons Information Service (NPIS) records telephone inquiries and TOXBASE sessions 
concerning GHB and GBL; TOXBASE is the primary NPIS clinical toxicology database. These data are 
not a direct measure of the frequency of toxicity or hospital admissions, but do provide an indirect 
measure, and also reflect what patients think they have used (NPIS, 2013). Figures from the agency 
indicate that the proportion of telephone inquiries involving GHB fell from 0.046% in 2007/8 to 0.028% in 
2012/3, whereas for GBL the fall was from 0.017% to 0.012%. The proportion of TOXBASE sessions 
during the same period for GHB fell from 0.195% to 0.171%, but that for GBL rose from 0.028% to 
0.086%.
Patients typically present to EDs in a varying range of conditions, from initial confusion, dizziness or 
euphoria, to collapse and vomiting, through to loss of consciousness or coma (EMCDDA, 2002). 
Presentations are often related to altered conscious state (89%), psychological concerns or 
nausea/vomiting (Horyniak et al., 2014), as well as generally ‘feeling unwell’ and having low body 
temperature (Krul et al., 2011). The typical characteristics reported in a study of 505 admissions to a 
Spanish ED for GHB intoxication was young (mean age 24.7 years), male (68%), at weekends (89%), 
early morning (75%), by ambulance (98%), Glasgow Coma Score <12 (72%), with co-consumption of 
alcohol (64%) and use of other illicit drugs (76%): amphetamines and derivatives (30%), cocaine (28%), 
ketamine (11%), cannabis (9%), others (5%) (Galicia et al., 2011). Symptoms were more severe for those 
who had taken GHB with other substances. These characteristics are very similar to those found by 
Lietchi et al. (2006) in a study of 65 GHB/GBL ED admissions: male 63%; median age 24 (range 16-41) 
years; co-intoxicants of alcohol or illicit drugs (mainly cocaine and MDMA) 65%; presenting with coma 
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83%. Bradycardia was observed in 38% of cases, hypotension 9%, hypothermia 48%, agitation 17%; 
vomiting 31%.
The most common clinical features of GHB toxicity are: neurological depression, bradycardia, hypotension 
and mild hypothermia. The concurrent use of other substances, including alcohol may contribute to other 
clinical symptoms such as vomiting and non-responsive coma (Wood et al., 2011). This is of particular 
importance in respect of alcohol (Barker et al., 2007; Kim et al., 2007; Liechti et al., 2006).
Cases of toxicity involving GBL and 1,4-BD are similar to GHB presentations, and are consistent with in 
vivo conversion of these substances to GHB (EMCDDA, 2002). An intoxication from GBL was reported by 
an ED concerning a 36-year-old woman who was hospitalised due to her comatose state and loss of 
adverse effects reflexes (Lenz et al., 2008). A UK case involved a 44 year-old male who suffered coma 
and life-threatening respiratory depression after an accidental overdose of GBL contained in a “health 
drink” (Dupont and Thornton, 2001). Two cases were recently reported from the Netherlands involving 
males aged 25 and 45 years, who both lost consciousness but recovered 16 h and 12 h later (van Vugt 
and Hofhuizen, 2012). Roberts et al. (2011) report that a patient who ingested a ‘massive’ dose of GBL 
with suicidal intent suffered severe metabolic acidosis and an asystolic cardiac arrest, but survived 
following treatment. In a similar case involving GBL ingestion the metabolic acidosis was accompanied by 
a highly increased anion- and osmolal gap; a GHB plasma level of 4398mg/L was recorded. Treatment 
including haemodialysis led to a full recovery (Heytens et al., 2014; Neels et al., 2014). It is hypothesised 
that the simultaneous intake together large quantities of alcohol (blood alcohol level of 279mg/dL) 
disturbed the metabolism of GHB with a consequent long-lasting acidosis and coma (Heytens et al., 
2014).
2.12 Fatalities
One measure of the risks inherent in the misuse of GHB and its prodrugs GBL and 1,4-BD is deaths 
associated with their use. GHB-related fatalities have been reported primarily from Western countries, 
such as the USA, Canada, Australasia, and Europe (Caldicott et al., 2004; EMCDDA, 2008; Simonsen et 
al., 2015; Zvosec et al., 2011). This measure is often used as part of a range of indicators/parameters in 
national and international risk assessments of substances of concern (EMCDDA, 1999; Nutt et al., 2007; 
van Amsterdam et al., 2012) and provides “signals of emerging harms” (EMCDDA, 2014:8). It is difficult to 
undertake epidemiological comparisons between and within countries for several reasons, including
(EMCDDA, 1998): lack of systematic data on the topic; absence of routine hospital and forensic testing for 
GHB and its prodrugs; little standardisation in the identification, investigation, recording and certification of 
drug-related fatalities at local, national and international levels; lack of ICD coding for GHB and analogues 
as a cause of death (Zvosec et al., 2011); and no consensus on the post-mortem blood and urine 
concentrations to be used to distinguish between endogenous and exogenous origins/sources of GHB.
Several reports and papers have now been published documenting significant numbers of deaths 
associated with recreational GHB use (e.g. Caldicott et al., 2004; Knudsen et al., 2010; Kugelberg et al., 
2010; Zvosec et al., 2011), as opposed to single case and small case series a decade ago (Davis, 1999;
DEA, 2002; Karch et al., 2001; Morbidity and Mortality Weekly Report, 1997; Zvosec et al., 2011). Many 
other fatalities allegedly involving/attributed to GHB have been reported in both the printed media and on 
the Internet (e.g. Erowid, 2013a) but these do not necessarily translate into actual officially-confirmed 
deaths. The key features emerging from these case-series are briefly described here. However, there is 
considerable overlap between Zvosec et al.’s overview (2011) and other sources. 
The main demographics of decedents are: mostly male (range 69-91%); average age 25-28 (range 15-53) 
years, males tending to be older than females by about 5 years (Caldicott et al., 2004; Kugelberg et al., 
2010); and mostly White (94%; Zvosec et al., 2011). Deaths have been ascribed to accidental overdoses, 
suicide, and drug-impaired driving. However, in certain cases there was a suggestion of alleged 
surreptitious administration of GHB via a “spiked drink” (Elliott, 2003). There is at least one death 
associated with complications arising from GHB withdrawal (Dyer et al., 2001). In the majority of reported 
cases attributed to GHB, the mechanism of death has been attributed to respiratory depression. For 
example, cardio-respiratory arrest accounted for 213/226 (94.2%) of the deaths between 1995 and 2005 
reviewed by Zvosec et al. (2011).
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Zvosec et al. (2011) classified deaths using a combination of GHB concentrations above their cut-off level, 
death investigations, and cause of death rationales to derive the following categories: “drug-caused” –
direct and toxic effects of GHB caused/contributed to death; “drug-related” – GHB intoxication associated 
accidents that directly caused death (e.g. drowning, road traffic accidents); and “indeterminate” – GHB 
detected above cut-off (50mg/L in blood (bl), 20mg/L in urine (ur)) but its role in the cause of death was 
unclear. The proportions occurring in each category were: “drug-caused” 91.6%, “drug-related” 5.8%, and 
“indeterminate” 2.6% respectively. Knudsen et al. (2010), using a cut-off of 30mg/L blood, employed the 
following categories: GHB poisoning without influence of any other drugs and no other substances 
detected; GHB poisoning with minor influence of other drugs on GHB as well as other drugs but other 
drugs presented concentrations within therapeutic ranges and were less than 5; and GHB poisoning with 
a major influence of other drugs were positive for GHB as well as other drugs. All opiates were included. 
All cases that presented with more than 5 different substances even if concentrations were low because 
interactions with a negative influence on outcome could not be excluded. The proportions occurring in 
each category were: 8.7%, 39.1% and 52.2% respectively.
The mode of misuse of GHB frequently involves the use of other substances. The presence of alcohol has 
been noted to range from 20-37% of fatal cases; cocaine 8-26%; codeine 18-22%; morphine 16-26%; 
amphetamines 10-35%; diazepam 22-26%; and MDMA 2-20%. Zvosec et al. (2011) report that 28% of 
cases involved GHB on its own, GHB + one or more CNS depressant 27%, GHB + 1 or more stimulants 
9%, GHB + 1 or more CNS depressant and stimulants 13%. The presence of alcohol and other 
depressant or psychoactive substances is widely believed to exacerbate the toxic effects of GHB 
ingestion, e.g. causing respiratory depression (Louagie et al., 1997; Zvosec et al., 2011), or even 
aspiration and asphyxiation. Therefore, the presence of such substances in deaths involving GHB should 
be taken into consideration when assessing fatalities attributed to GHB intoxication (Kugelberg et al., 
2010; Snead and Gibson, 2005). Ferrara et al. (1995) reported a death involving GHB and heroin 
(diacetylmorphine), a high concentration of morphine was detected in the blood (770 mg/L). In five other 
reported GHB deaths, ethanol has also been involved at significant concentrations (Davis, 1999; Elliott, 
2000, 2001). In these cases, the mechanism of death was recorded as respiratory depression. More 
recently a death involving GHB and mephedrone was noted in Italy (Aromatario et al., 2012).
Due to the previous anaesthetic therapeutic use of GHB, data relating to plasma concentrations and 
effects were largely based on IV administration rather than oral administration (the primary route of 
abused GHB). Such IV studies had indicated that plasma concentrations exceeding 260 mg/L could result 
in deep sleep (Helrich et al., 1964).  In cases of non-fatal GHB intoxication resulting in various degrees of
sedation, plasma and urine concentrations are typically greater than 100 mg/L and 1000 mg/L respectively 
(Couper and Logan, 2000; Elliott, 2004b). In fatalities, post-mortem blood and urine concentrations have 
been reported to be between 27 - 1400 mg/L and up to 6000 mg/L respectively (Baselt, 2008; Duer et al., 
2001; Karch et al., 2001; Mozayani et al., 1998). Sporer et al. (2003) report a median blood level of 
180mg/L (range 45-295). Kugelberg et al. (2010) report a blood level of 2220mg/L.
Reports of GBL-related fatality have been infrequent: two in Germany (Lenz et al., 2008), one in the USA 
(Duer et al., 2001), and one in the UK (Dargan et al., 2009; included in the present sample). The German 
fatalities involved males aged 38: the first had GHB equivalent concentrations of cardiac bl 1089mg/L, 
femoral bl 957mg/L, urine 1019mg/L, gastric 14,464 mg/L, bl ethanol 67mg/dL, amphetamine bl 
207.4mg/L, MDMA 5.8mg/L; the second case had a GHB blood concentration of 165mg/L and urine level 
of 916mg/L. The cause of death in each case was attributed to GHB intoxication; the manner of death was 
suicide in the first case and accidental in the second one. A non-fatal intoxication of a female aged 36 had 
a GHB serum level of 161mg/L and urine level of 2594 mg/L. The US case involved a 38 year-old male 
whose death was attributed to chronic drug abuse from the combined effects of the drugs detected. Post-
mortem toxicology was positive for multiple drugs including GHB, GBL, MDMA, morphine, codeine, and 6-
MAM. The concentrations of drugs detected in the urine were: GHB 320 mg/L, GBL 66 mg/L, 6-MAM 1.12 
mg/L, codeine 0.11 mg/L, and morphine 3.10 mg/L. MDMA was detected in the urine. Only morphine was 
detected in the post-mortem heart blood at a concentration of 0.07 mg/L. The contents of the bottle 
recovered had a determined concentration of 19,000 mg/L GBL. GHB testing in the ocular fluid and brain 
detected levels of 37 mg/L and 44 mg/kg, respectively. The depressant action of GHB, GBL, and heroin 
may have caused the decedent to become unconscious for a period of time prior to death allowing him to 
metabolise the majority of the drugs from the blood. The manner of death was accidental (Duer et al., 
2001).
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Deaths involving 1,4-BD are also rare. One death in New Zealand has been linked to the use of 1,4-BD. It 
involved a 22 year old male who had consumed 15 ml of 1,4-BD. He had a seizure but was found not 
breathing 3 hours later. The blood level of GHB on admission to hospital was 220 mg/L. A chest X-ray 
indicated aspiration pneumonia. Brain death was confirmed the next day. There was no evidence for the 
use of any other drugs. It was concluded from the post-mortem examination that death resulted from 
complications due to a 1,4-BD overdose. Vomitus was inhaled resulting in pneumonia, shock, 
cardiac/respiratory arrest and brain damage (Theron et al., 2003). A case in the USA involved a 21 year-
old male who died of accidental intoxication of 1,4-BD. The peripheral blood concentration was 70mg/L 
and 78mg/L for cardiac blood, the urine level was 870mg/L. The weighted mean for the GHB 
concentration was 303 mg/L in the heart; 1513 mg/L in the urine, and 260 mg/kg in the brain (Duer et al., 
2001). Kugelberg et al. (2010) found 1,4-BD in the post-mortem toxicology of 4 deaths attributed to GHB 
intoxication (2 intentional, 1 accidental, 1 undetermined intent). No other substances were found. 
Concentrations were: ur 3400; bl 42, ur 1200; bl 25; bl 25 mg/L. The highest levels were in the intentional 
cases.
A number of deaths have been associated with the use of Xyrem® (sodium oxybate), a pharmaceutical 
preparation of GHB initially approved for treatment of narcolepsy with cataplexy. One death appears 
associated with Xyrem® abuse, with extremely high post-mortem blood GHB levels documented (bl 
3500mg/L, vitreous 1800mg/L) together with drugs, including amphetamines. Although post-mortem blood 
GHB levels in two other deaths are consistent with therapeutic levels (110 and 141mg/L), cause and effect 
cannot be established although other drugs were again present, including CNS depressants. It is likely 
that Xyrem® contributed to the deaths in this way (Zvosec et al., 2009). Another case involved a 53-year-
old woman undergoing treatment with Xyrem® for narcolepsy; the decedent was also prescribed tramadol, 
gabapentin, cetirizine, modafinil, and carisoprodol. Toxicological analysis of the blood revealed GHB 
165.6 mg/L, and 90.7 mg/L in the urine. Blood GHB concentrations in the range 156-260 mg/L have been 
reported to induce moderately sound sleep. The combined use of prescribed CNS
depressant drugs, together with her problematic sleep apnoea, and snoring (both contraindications for 
GHB use) were determined to have caused this subject's death. The manner of death was determined to 
be accidental (Akins et al., 2009).  One death has been associated with the use of Alcover®. This case 
also involved moderate blood levels of morphine (bl 0.77, vitreous 0.3mg/L) together with GHB levels in 
blood 11.5, vitreous 84.3 and urine 258.3 mg/L (Ferrara et al., 1995).
Kilgore and Petullo (2010) note that an Agency Xyrem® Post-marketing Review between 17 July 2002 and 
27 July 2010 recorded 91 reports of death, of which 21 were determined unlikely related to Xyrem®, 63 
were indeterminate causality due to insufficient data, and 7 cases in which a contribution by Xyrem® could 
not be excluded. In general, at the time of death, the patients received recommended Xyrem® doses, and 
were using concomitant CNS depressants such as alcohol and sedative hypnotics. The causes of the 7 
deaths were: unknown (5) drowning (1), and completed suicide (1). Wang et al. (2011) reported that 
worldwide there had been a total of 227 deaths in sodium oxybate patients between 2002 and May 2011. 
Cause of death was documented in only 88 (39%) of the cases, some of the major causes being: 
overdose (19 cases); cardiac events (17); malignancy (15); suicide (8); accidental death (7); 
cerebrovascular accident (5); and respiratory events (5).
Whilst the most comprehensive review of case series of GHB-associated deaths is that of Zvosec et al. 
(2011), it mainly focused on toxicity and trauma based on data obtained from a convenience sample of 
medical examiners/coroners in the USA, UK and Canada and from media reports. It provides a useful 
summary of basic demographics, ethnicity and manner of death. It provides a synthesis of blood GHB 
levels, details of dosages and clinical effects where available.
There have been several previous reports on UK GHB/GBL fatalities, including single case studies such 
as Elliott (2000) and Jones (2001). Details of GHB concentration, co-intoxicants and cause of death in 47 
cases occurring between 1993 and 2005, identified by the National Programme on Substance Abuse 
Deaths (NPSAD), where GHB/GBL was found at post-mortem and/or implicated in death were included as 
an appendix in the ACMD risk assessment of GBL and 1,4-BD (ACMD, 2008:34-44; EMCDDA, 2008:21). 
One death involving GBL has been reported by Dargan et al. (2009). Here we give details of the largest 
number of fatalities associated with GHB and its pro-drugs to be documented so far in the UK. Not only 
are a range of key demographic features described but also circumstances of death, causes of death, 
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detailed toxicological levels for blood and urine, drug combinations, etc. for these cases. The existing 
literature on dosages and GHB/GBL levels in human tissues is presented for a range of scenarios. 
3. UK GHB/GBL-related fatalities
3.1 Methods and source(s) of UK data 
3.1.1 National Programme on Substance Abuse Deaths (NPSAD)
NPSAD regularly receives information from coroners on a voluntary basis on deaths related to drugs in 
both addicts and non-addicts in England and Wales, Northern Ireland, the Channel Islands and the Isle of 
Man. Since 2004, information has also been received from the Scottish Crime and Drug Enforcement 
Agency and the General Register Office for Northern Ireland. Since 1997 details of about 30,000 deaths 
have been received. The annual response rate from coroners in England and Wales to NPSAD has been
consistently over 75%. To be recorded in the NPSAD database as a drug-related death, at least one of 
the following criteria must be met: (a) presence of one or more psychoactive substances directly 
implicated in death; (b) history of dependence or abuse of drugs; and (c) presence of controlled drugs at 
post-mortem. Ethical approval is not required in the UK for studies whose subjects are deceased, and 
solely involves retrospective reviews of death records. 
3.1.2 Case identification
A range of documents are contained in coronial inquest files, although the variety differs from case to 
case. Typically, the coroner has access to: statements from witnesses, family and friends; General 
Practitioner records (if the deceased is registered with one); reports from ambulance, police or other 
emergency services; hospital EDs and clinical ward reports; psychiatric and substance abuse team 
reports; as well as post-mortem and toxicology reports.  
In 2007 anonymised information was exchanged between the first and sixth authors in order to identify 
further cases (N = 2) and toxicological data. In 2009, enquiries were also made of the General Register 
Offices for England and Wales (through the Office for National Statistics - ONS), Scotland; and Northern 
Ireland to ascertain if there were any further cases known to them. Searches were made of the cause of 
death and toxicology text fields (where appropriate) of their electronic databases using the names for 
GHB, GBL and 1,4-BD. As a result of these initiatives, three further cases were identified in England that 
had not been reported to NPSAD. Contact was then made with the relevant coroners and details of these 
previously unknown cases were obtained and are included in the results presented here. Information 
provided from the drug-related deaths database maintained by the General Register Office for Scotland 
(GROS) indicated that there had been two additional cases in that country (in February 1999 and 
November 2001).  Both involved White males, aged 30 and 32 respectively. One case involved other 
drugs, and one GHB alone (personal communication to first author from Graham Jackson, 12 March 
2002). There have been none involving GBL or 1,4-BD (personal communication to first author from Frank 
Dixon, 15 July 2014). All cases registered by GROS up to the end of 2013 are included in this dataset. 
There have been no known deaths involving GHB or its derivatives in Northern Ireland (personal 
communication to first author from Northern Ireland Statistics and Research Agency, 18 July 2014).
Internet searches of toxicological as well as media websites revealed information on further cases and 
assisted in identifying potential new cases (about 10%). When the full text of the newspaper reports were 
not available on-line, it was necessary to view the original paper versions of the articles were retrieved. 
Media reports available for some cases were used to supplement the information provided on the NPSAD 
data collection form, especially where access to the full coronial files was not possible. Members of the 
London Toxicology Group (LTG) were also canvassed to see if they were aware of any cases; no further 
cases were reported. In all but two cases, full details of named individuals were known and thus prevented 
double-counting of cases. In the remaining two cases (from GROS – see previous paragraph), although 
anonymised, sufficient detail was provided to enable the exclusion of cases already known.
A retrospective study design was employed to identify relevant cases associated with the use of GHB, 
GBL and 1,4-BD by searching the NPSAD database with the following terms - 'GHB', 'GBH', ‘GBL’, ‘1,4-
BD’, ‘BDO’, 'gamma hydroxybutyrate', ‘gamma butyrolactone’ and 'sodium oxybate', and any variants in 
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spelling. The fields searched on the database were those holding data on - drugs present at post-mortem, 
cause(s) of death, verdict, accident details, and 'other relevant information'. 
3.1.3 Interpretation of toxicological levels
There has been a lengthy debate about what should be the appropriate minimum levels for GHB and its 
analogues in human ante- and post-mortem samples for its presence to be deemed non-endogenous in 
origin (Andresen et al., 2010). This is an important consideration as GHB is produced in the body after 
death (Moriya and Hashimoto, 2004; Sakurada et al., 2002), levels can vary according to the site from 
where the sample was taken (Mazarr-Proo and Kerrigan, 2005), and because of post-mortem blood 
redistribution (Pounder and Jones, 1990). Other factors to be taken into account when interpreting GHB 
concentrations include: longer storage time leads to higher sample concentrations; preservatives and 
additives may have an effect; storage temperatures; drugs such as valproate, phenobarbital, barbital and 
chlorpromazine may cause interactions with metabolic pathways (Andresen et al., 2010; Andresen-
Streichert et al., 2015; Busardò et al., 2014). Only about 5% of GHB is eliminated in urine as it is 
metabolised extremely quickly to carbon dioxide through the Krebs cycle (Brenneisen et al., 2004; Ferrara 
et al., 1992). Typically GHB ingestion can only be detected for about 12 h in urine (Brenneisen et al., 
2004), and 5-8 h in blood (LeBeau et al., 1999). However, a recent study of healthy volunteers 
administered doses of 2.1g (equivalent to a therapeutic dose for the treatment of narcolepsy) found that 
after 4-5 h the GHB concentrations in serum and blood fell below the analytical level of 1ug/ml and in 
urine after 10 h (Shröck et al., 2014).
For ante-mortem urine samples Mari et al. (2009) suggest a level of 3-10mg/L as indicating the possibility 
of exogenous GHB; whereas McCusker et al. (1999) and Crookes et al. (2004) suggest 5mg/L and 
Andresen et al. (2010) 6mg/L.  Others have proposed a 10mg/L limit for discrimination to identify 
exogenous GHB (Bosman and Lusthof, 2003; Brailsford et al., 2010; Elian, 2002; Elliott, 2003; Wood et 
al., 2011; Yeatman and Reid, 2003; Zvosec et al., 2011); however, the possibility of false negatives exists 
when using this cut-off level (Andresen et al., 2010). Levels of 1mg/L and 5mg/L have been suggested for 
blood (Chin et al., 1992; Shima et al., 2005; Shröck et al., 2014; Zvosec et al., 2011;). Elliott’s (2003) 
suggestion of 4mg/L for ante-mortem blood is endorsed by Andresen et al. (2010). These suggested cut-
offs are not to be seen as rigid requirements, but as aids to interpretation.
There is now a general consensus that post-mortem blood concentrations of >50mg/L and urine 
concentrations >10mg/L are indicative of GHB (and analogue) consumption (Bosman and Lusthof, 2003). 
Moriya and Hashimoto (2005) proposed 10 mg/L for urine and 30 mg/L for blood in decedents showing 
little or no putrefaction (post-mortem interval <48 h). This cut-off was supported for femoral vein blood 
samples by two recently published retrospective studies from Sweden (Knudsen et al., 2010; Kugelberg et 
al., 2010). However, Kintz et al. (2004) argue that detection of GHB in urine is not necessarily indicative of 
use, and that levels in blood above 50mg/L alone are insufficient to prove an exogenous source; 
triangulation is essential. Kugelberg et al. (2010) and others (Elliott 2004a; Moriya and Hashimoto, 2005) 
have used a cut-off concentration of 30mg/L in femoral blood. Zvosec et al. (2011) suggest cut-offs of 
50/20/7 mg/L for blood/urine/vitreous respectively for GHB, ≥ 1 mg/L for 1,4-BD blood levels. Andresen-
Streichert et al. (2015) suggest a cut-off of 30mg/L for venous blood, urine and cerebrospinal fluid. Some 
authors recommend analysis of urine in addition to blood samples because of typically (but not generally) 
lower GHB concentrations due to less post-mortem generation. Other authors suggest vitreous humour as 
the specimen of choice, in addition to femoral vein blood but the comparative data for this fluid are limited. 
As with other psychoactive substances, the levels of GHB found in fatalities overlap with levels found in 
drivers under the influence of the substance (Bosman and Lusthof, 2003; Pan et al., 2001) and 
therapeutic levels (Moriya and Hashimoto, 2004). In post-mortem peripheral blood samples, depending on 
the methodology used, high concentrations of GHB from zero to 197 mg/L could be measured, even in 
cases without GHB ingestion. These levels overlap with the range of reported fatal GHB intoxications with 
concentrations of 27 to 2937 mg/L and could possibly lead to misinterpretation as intoxication (Andresen 
et al., 2011). Concentrations in non-fatal intoxications as high as 551 mg/L have been reported (Couper 
and Marinetti, 2002; Elliott, 2004b; Van Sassenbroeck et al., 2007), whilst fatalities with concentrations of 
303 mg/L have been recorded (Duer et al., 2001; Marinetti et al., 2005).
3.1.4 Toxicological screening
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Historically, analysis for the presence of GHB was not performed routinely in clinical or post-mortem 
investigations in the UK or other countries (Caldicott et al., 2004; Jones et al., 2007). The drug and its 
prodrugs have been typically looked for only after a direct approach from the medico-legal investigators, 
often if anecdotal or circumstantial evidence points to its use (EMCDDA, 2002). If screening for other 
drugs proves negative, but signs and symptoms of drug influence have been noted, a search for GHB 
may be made. However, over the past decade the provision of this service has improved; it is not at all 
uncommon for GHB and its derivatives to be tested for in the UK (Korb and Cooper, 2014), USA, Sweden 
and certain centres in Australia. Since GHB is metabolised relatively quickly in the body, it may not be 
present in toxicology screens, even if they are made. Thus, the number of identified cases reported 
historically is likely to be an underestimation.
All cases reported here have either confirmatory evidence of GHB, GBL, etc. ingestion and/or the tissue 
levels are consistent with exogenous intake/misuse (as outlined in Section 3.1.3). 
3.1.5 Data analysis
Data entry and analysis were performed using IBM ® SPSS™ Statistics for Windows version 19
employing descriptive statistics. Data on blood, urine (and vitreous) GHB concentrations are presented as 
mean, median and range. Statistics for each test are based on all cases with valid data for the variables 
used in that test. A two-tailed p-value of ≤0.05 was considered to indicate statistical significance.
3.2 UK Results 
3.2.1 Number of cases
A total of 159 fatalities that met the above inclusion criteria were identified on the NPSAD database as 
having been reported by September 2013. The first known death in the UK related to GHB consumption
occurred in 1995. Of these 159 cases, the role of GHB was uncertain in one case.  At least 55 (34.6%) are 
considered to have involved the use of GBL; there were none attributed to the taking of 1,4-BD. Although 
the number of deaths was low (mean 1.5 p.a.) during the second half of the 1990s, there was a notable
increase in 2001 and 2002 (7 and 6 cases respectively), followed by a rapid fall to just one case in 2003 
(Figure 1). The period from 2004 to 2009 witnessed a rapid and progressive rise to 25 deaths, this peak 
being maintained in 2010 at 21. However, this was followed by a steep decline in 2011 (to 10), followed by 
a doubling to 20 in 2012. 
< insert Figure 1 about here >
3.2.2 Socio-demographics
The mean age of decedents was 32.1 (range 18.9 - 60.1) years, males being 2.7 years older than females 
on average (Table1). About 91% were aged less than 45 years. Most were male (81.9%). Where known, 
the ethnicity of most (91.9%) of the deceased was described as 'White'. Where place of birth was given, 
77.0% were born in the UK, 10.7% in another European country, and 8.2% elsewhere. Where known, 
70.7% were in employment, 17.9% were unemployed. Half (51.6%) were living with someone else and 
27.0% lived alone. Information on prescribed psychoactive medications was available for 90 cases (Table 
2). In 29 (32.2%) medications were prescribed; most were antidepressants, antipsychotics or 
benzodiazepines. Where information was available on past drug use, 69.8% were known to have 
previously used drugs or to have been dependent on them. Ten out of 56 individuals (17.9%) were known 
to have been injectors at some time.
< insert Table 1 about here >
< insert Table 2 about here >
3.2.3 Circumstances of death
Page 19 of 61
Ac
ce
pte
d M
an
us
cri
pt
19
All of the deaths reported thus far have occurred in Great Britain: England 123, Scotland 27 and Wales 9 
(Table 3). Where known, the majority of cases died at home or in another private residence (friend’s or 
relative’s home) (77.1%), and 14.6% in hospital (Table 4). From the few details available, it seems that in 
many instances there was an assumption that the deceased would 'sleep it off'. The manner of death in 
most cases was accidental (79.2%), with 6.9% being regarded as suicidal and undetermined in 13.2% of 
cases. This closely reflects the verdicts of coroners or other formal determinations, where 
accidental/misadventure verdicts were given in 60% of cases; along with drug-related conclusions being 
recorded for a total of 35 cases (22%), non-dependent abuse of drugs (14%), abuse of drugs (5%) and 
drug dependence (3%); and (possible) suicides for the remaining 29 cases (18%). Deaths were 
proportionately (36%) more likely to occur at weekends (between Saturday and Sunday) than on a week-
day (χ2 = 4.463, df = 1, p = 0.0346).
< insert Table 3 about here >
< insert Table 4 about here >
3.2.4 Events leading to death
In at least six cases GHB was sourced from the Internet as well as four cases of GBL (including one 
decedent who ran a site selling the substance). Another was a dealer in GBL and one made his own GBL.
In line with half of the deaths occurring at home, half of the events leading to such events also occurred at 
home or that of another person. In many instances, such deaths followed recreational use of GHB in these 
settings. A range of other locations witnessed GHB consumption including pubs/clubs, music festivals, 
motor vehicles, and open spaces (Table 4). 
GHB/GBL consumption was not always for recreational purposes, for example: body-building/fitness; to 
aid sleep; to prevent alcohol craving; and to enhance sexual experiences. Whilst there were at least 7 
suicides and 2 cases of probable suicide where GHB/GBL was deliberately consumed so as to apparently 
cause death, a number of deaths (n = 7) were ‘accidental’ in the widest sense of the term – being 
mistaken for water, or in drinks not intended for the deceased.
3.2.5 Cause of death
When considering the underlying cause of death (Table 5), the majority of deaths were attributed to 
accidental poisoning (76.7%), with intentional self-poisoning (6.3%) and poisoning of undetermined intent 
(12.6%). In terms of the proximal (immediate) cause of death, the proportions for these categories fall to 
59.7%, 5.7% and 8.8% respectively. There were more deaths where natural causes played a role as a 
consequence of taking GHB/GBL and/or other substances. The principal causes in this category can be 
grouped as follows: respiratory (6.9%); cardiac (2.5%); cardio-respiratory (2.5%); aspiration of gastric 
contents (3.8%); asphyxia/anoxia/hypoxia (3.1%).
< insert Table 5 about here >
3.2.6 Post-mortem toxicology
Blood concentrations of GHB > 0mg/L were available in 118 (73.8%) of the 159 cases; of these 13 
(11.1%) were ≤30mg/L and 3 (2.6%) were >30mg/L but ≤40mg/L; 5 (4.3%) were >40mg/L but ≤50mg/L; 
and 96 (82.1%) were >50mg/L. The mean blood level was 481 (range 0 – 6500; S.D. 758.26) mg/L (Table 
6). Urine levels were available for 36 cases (22.6%); 5 (13.9%) of these were ≤10mg/L and 31 (86.1%) 
were >10mg/L. The mean urine level for cases was 1444.17 (range (0 – 7600; S.D. 1632.42) mg/L.
< insert Table 6 about here >
The commonest groups of substances found, apart from GHB/GBL, were: alcohol; stimulants (cocaine, 
amphetamine/methylamphetamine, MDMA/MDA, mephedrone); benzodiazepines (principally diazepam); 
opiates/opioids; ketamine; and cannabinoids (Table 7). There was a mean of 3.47 post-mortem
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substances, reflecting polysubstance use.  The range of substance types listed above were also evident in 
the most common combinations reported (Table 7). The most prominent were: GHB/GBL and alcohol 
(13.8%); GHB/GBL alone (12.6%); and GHB/GBL and stimulants and alcohol (11.9%).
< insert Table 7 about here >
3.2.7 Drugs implicated
GHB /GBL was implicated on its own in more than one-third (36.5%) of cases (see first 4 rows of Table 6); 
GHB/GBL and alcohol alone were implicated in 13.8% of cases; GHB/GBL and other drugs in 28.3%; and 
GHB/GBL with other drugs and alcohol in 14.5%.
The typical profile of cases where GHB/GBL was the sole substance implicated in death (n = 59) is: male 
(88%); mean age 32 years. Where known, victims were of White ethnicity (89%); and with a history of 
drug use/dependency (67%). Most deaths (72%) occurred at the home of the deceased or a 
friend/relative, usually following consumption in such locations (Table 8).
< insert Table 8 about here >
3.3 Discussion 
3.3.1 Number of cases
Since the first known death in the UK associated with the ingestion of GHB and its prodrugs in 1995, there 
have been a minimum of 159 cases in which these substances were implicated. Of these, at least 55 
(34.6%) involved GBL, increasing between 2006 and 2010 and then declining. The increase in NPSAD 
GHB/GBL deaths occurring in 2012 is echoed by an increase in the number of deaths involving these 
substances registered during 2013 in England and Wales (ONS, 2014). The patterns shown in Figure 1 
reflect, to a certain extent, the effects of control of GHB in 2003 and GBL in 2009 in terms of a 
displacement from controlled to illegal forms of the substance(s) and then a fall, as was seen with GHB 
and GBL in Switzerland (Liechti et al., 2006), GHB in Sweden (Mikelsson, 2005) and the Netherlands 
(Van Amsterdam et al., 2014), and mephedrone in the UK (Corkery et al., 2012).
The overall proportion of all deaths notified to NPSAD for the period 2000-12 accounted for by GHB/GBL 
was 0.58% (range 0.06 – 1.24). The total number of cases reported here is likely to be an under-estimate 
due to: (a) incomplete geographical coverage by the Programme; (b) unidentified cases due to a lack of 
historic systematic screening for GHB and its prodrugs in post-mortem toxicology of suspected drug-
related fatalities; (c) further cases awaiting the conclusion of formal investigations; (d) the voluntary nature 
of the NPSAD reporting system; etc. For example, media reports suggest 4 further GBL deaths have had 
inquests completed on them by the end of July 2014. Of these, one occurred in 2011, two in 2012 and one 
in 2013. Two additional GHB deaths have been reported for 2012 and one for 2013. These additional data 
were not included in this study.
Presently, analysis for the presence of GHB is not usually performed routinely in clinical or post-mortem 
investigations in the UK, although it is not all uncommon in the USA and certain centres in Australia. 
Hence the number of identified cases reported here is likely to be an underestimation. Since GHB is 
metabolised relatively quickly in the body, it may not be present in toxicology screens, even if they are 
made.
3.3.2 Socio-demographics
About 82% of victims were male. This proportion is only slightly higher than that seen in ‘typical’ NPSAD 
cases (about 75%). A probably elevated contribution to this male proportion (about 11%) was made to this 
sample by males known to be homosexual; with two further deaths recently reported for 2012 that 
occurred in the same venue (a sauna catering for a gay clientele) as a case included here (Cheston, 
2014). (Information on sexual orientation was found in coroners’ records, e.g. known to have a male 
partner, engaged in homosexual activities around time of death, etc.) The proportion of homosexual men 
in the general population of the UK is about 1.5% (ONS, 2013). However, in some areas, such as Brighton 
Page 21 of 61
Ac
ce
pte
d M
an
us
cri
pt
21
& Hove, the Lesbian Gay Transsexual and Bisexual (LGTB) community may account for as much as 15% 
of the local population; Durgahee et al. (2014) report that 4/5 of their GHB/GBL dependence sample in the 
area identified themselves as being from the LGTB community. NPSAD has been notified of 4 GHB/GBL 
deaths in this area (Table 3). The finding of the present study in respect of the gender split (percentage 
male) lies between those of Caldicott et al. (2004) of 80% and Kugelberg et al. (2010) at 86%; Zvosec et 
al. (2011) report a rate of 69% and Knudsen et al. (2010) one of 91%.
The mean age at death in this study was 32.1 (range 18.9 – 60.1) years compared to 38.5 (range 0.0 -
99.0) years in typical NPSAD cases during the same period, probably reflecting the different nature of the 
two samples - recreational versus mostly problematic users. The median age of those dying in 2012 with a 
known history of drug use was 38 years (Corkery et al., 2014a); for all other deaths it was 40 years. The 
average age is higher than for GHB fatalities in the USA; here 40% of deaths were amongst those aged 
15-24 and a further 27% aged 25-29 (DEA, 2002). The large age range reported here is consistent with 
the IDMU survey results (Atha and Davis, 2001, 2002).
As with most reported GHB-related deaths (in the US and elsewhere), the cases detailed here mostly 
involved Caucasian individuals (92% where known).  Where known, most victims (94/122; 77.0%) were 
born in the UK, but there were also a number of individuals born elsewhere in Europe (13; 10.7%) or on 
other continents (10; 8.2%). 
Where known, the majority (87/123; 70.7%) of cases were in employment and more than half (82/127; 
64.6%) were living with others. This is in distinct contrast to typical drug-related deaths (366/1154, 31.7%; 
and 521/1170, 44.5% respectively) (Corkery et al., 2014a). This, no doubt, reflects the lower mean age of 
the GHB/GBL cohort. 
A past history of drug use was known for 106 cases; of these 74 (70%) had such a history. About 18% of 
the decedents were known to be injectors; this is lower than the 41/90 (46%) of ED cases reported by 
Boyd et al. (2012). Where the circumstances were known, the majority (82/115; 71%) of deaths followed 
recreational use, often by individuals with a history of substance use. Several (n = 6) cases involved the 
use of GHB/GBL directly in connection with sexual activities. Where information was available, a small 
number of individuals used of GHB to aid sleep (n = 4) or to assist in body-building (n = 4), whilst two 
others were known to use gyms regularly.
The temporal pattern of most GHB/GBL deaths occurring in the UK on Saturday or Sunday (36%, 
compared to an expected proportion of 28.6%) probably reflects higher consumption rates on Friday to 
Sunday. These findings echo ED admissions in other studies (Boyd et al., 2012; Liechti et al., 2006; Miró 
et al., 2002; Munir et al., 2008).
All parts of the UK, except Northern Ireland, have experienced GHB/GBL deaths. None had been reported 
so far from the Islands by the end of September 2013. Many cases appear to have occurred in 
Metropolitan areas. Of note is the fact that 17 cases (12% of the overall total and 48% of the total for 
Greater London) occurred in just one coroner’s area (Inner South London). Many of these cases involved 
homosexual males who had frequented well-known gay clubs in the Vauxhall area. A number of deaths in 
2005 and 2006 connected with these clubs led to materials being prepared to give advice on safer use of 
GHB/GBL (Daily Mail, 2006; FIRE, 2006). Clubs started issuing warnings that they had a ‘zero tolerance’ 
approach to the possession and use of drugs including GHB and its derivatives. For example, FIRE, a 
well-known gay venue, provided information to clubbers on the adverse effects of GHB and GBL
(http://www.harderfaster.net/text/news/11814). It also had fully qualified paramedics on duty whilst the 
club was open to the public, with a close working partnership with the London Ambulance Service. 
However, these dangers still persist (Hopkins, 2012) and there is so much concern that community 
leaders in the area arranged an open discussion with guest panellists in May 2013 (Zapata, 2013).
3.3.3 Post-mortem toxicology and other findings
There remains some uncertainty about what constitutes a fatal level of GHB/GBL. See Table 9 for a 
summary of findings from previous studies. Detailed information for the cases reported here is available in 
Table 10. Suggested estimates of GHB blood levels sufficient to cause death include those given by 
TIAFT (www.TIAFT.org) - 280 mg/L, and Kugelberg et al. (2010) – 300mg/L. Knudsen et al. (2010) argue 
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that because of the wide range of factors influencing outcomes after a severe overdose e.g. anatomical, 
physiological, pharmacological, etc., a level of toxicity can only serve as a guide for when severe toxicity 
should be suspected/investigated. Galloway et al. (2000) suggest that a potential lethal dose may be 
between 15 and 50g (250-750mg/kg) for a 70 kg person. Knudsen et al. (2010) found that although blood 
concentrations of GHB were higher with alcohol than without (320 vs. 235mg/L) these findings were not 
statistically significant. The median concentration in urine was twice as high in cases negative for alcohol, 
but not statistically significant. A lower GHB urinary value may suggest higher toxicity with alcohol 
consumption since less GHB has been excreted into urine before death, thereby reflecting a slower 
metabolism and earlier death (Knudsen et al., 2010).
Post-mortem blood concentrations found in this study range from 8 to 2794 mg/L for polysubstance 
deaths and from 159 to 6500 mg/L for cases involving GHB (or its derivatives) on its own (Table 6). These 
results are in line with previous findings for GHB-associated fatalities, medical examiner cases, and cases 
with known GHB uptake (Table 9). However, some post-mortem levels reported here are in excess of 
previous reports. It is important to note that 82% of cases had GHB levels > 50mg/L where blood levels 
were reported, indicating exogenous intake. The remaining cases (with lower levels) had evidential proof 
for exogenous intake. 
GHB/GBL alone was identified at post-mortem on 58 occasions (36.5% of the present sample). ONS 
figures for death registrations in England and Wales during the period 1993-2013 show that overall the 
proportion of GHB/GBL cases involved the drug without other drugs was 54.7%, and with alcohol 36.7% 
(ONS, 2014). The findings in the present study confirm the results of other studies (e.g. Caldicott et al., 
2004) that GHB (and GBL) can prove fatal on its/their own. The majority of cases involved the ingestion of 
at least two other substances, typically combinations of any of the following: alcohol; stimulants; 
diazepam; opioids; and ketamine. Co-ingestion with other sedatives such as alcohol or ketamine 
increases the likelihood of intoxication (Brunt et al., 2014). Polydrug intoxication is likely to be a significant 
factor in the cases presented here, in line with Kugelberg et al. (2010). There was considerable variability 
in the range of GHB/GBL levels at post-mortem. In many instances the effects on respiratory depression 
of GHB/GBL were enhanced by the presence of alcohol (46%) and other CNS depressants such as 
benzodiazepines, antipsychotics, and opiates/opioids. Both alcohol and GHB are metabolised by alcohol 
dehydrogenase and potentiate the effects of each other (Galloway et al., 2000; Smith et al., 2002; Vree et 
al., 1975). Recent animal studies have concluded that alcohol potentiates the sedative and respiratory 
depressant effects, especially the tidal volume, of GHB, thereby increasing the risk of death (Morse and 
Morris, 2013). The findings of the present study for humans echo those of Adinoff et al. (1988), Altose and 
Hudgel (1986), Mason and Kerns (2002), and Zvosec et al. (2011).
High doses of GHB can cause cardio-pulmonary depression (McDowell, 2000). These effects are made 
worse by being consumed with other substances. In the present study GHB was used with alcohol in 14% 
of cases; with other drugs in 28%; and with other drugs and alcohol in 15%. As Table 5 demonstrates in 
respect of proximal cause of death, the consumption of GHB/GBL alone or with other CNS depressants 
led to cardiac, respiratory and cardio-respiratory failure, the reduction of oxygen to the brain (asphyxia, 
anoxia, hypoxia), and physical obstruction of the airways due to aspiration of gastric contents. Together 
these cases account for about one-fifth (19%) of cases. If fuller information was recorded in the medical 
certificate of death in respect of the actual mechanism(s) of death, this proportion is likely to be much 
higher since one would expect more deaths involving these mechanisms. Vomiting is often seen in GHB 
intoxications (Mason and Kerns, 2002), especially with alcohol ingestion (Liechti and Kupferschmidt, 
2004), and can lead to asphyxiation.
3.3.4 Pre-existing medical conditions
Pre-existing medical conditions (see next paragraph) may have contributed to death or been exacerbated 
by the use of GHB/GBL in some cases. Respiratory diseases/conditions, such as those reducing the 
lungs’ ability to supply oxygen to the cardio- and cerebral-vascular systems, will be compromised by the 
use of the drug(s), especially with co-administration of other CNS-depressants. In the present study only 
one case had a known history of respiratory problems (emphysema) which was considered to have 
contributed to or caused death.
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Bradycardia has long been recognised as a complication in the therapeutic use of GHB and also in those 
using it recreationally (Mason and Kerns, 2002). There have been some cases of GHB causing other 
cardiac problems, typically arrhythmias; where it has it often has been co-ingested with traditional 
stimulants such as cocaine (Mason and Kerns, 2002), or more recently with mephedrone (Aromatorio et 
al., 2012). In two cases there was a known history of heart disease (coronary artery atheroma were 
severe stenosis; coronary atherosclerosis and hypertensive heart disease) and in a third instance the 
post-mortem found an enlarged heart consistent with dilated cardiomyopathy leading to pulmonary 
embolism. Cardiac problems caused/exacerbated by stimulant use were noted in three cases and caused 
solely by GHB in another case. These problems led to cardiac failure in three instances and to ischaemic 
heart disease and severe coronary atheroma in a fourth case. Only two of those on prescribed medication 
were known to have used stimulants on a regular basis compared to 16 of the remaining cases. The latter 
were more likely to have a history of using non GHB/GBL drugs than those on medication (29 vs. 4). 
Tricyclic antidepressants can cause sodium channel blocking leading to cardiac complications such as 
ventricular tachycardia and torsades de pointes arrhythmia (Gheshlaghi et al., 2012). Co-ingestion of 
tricyclic antidepressants may be a risk factor for GHB/GBL usage, especially when taken together with 
stimulants. In the case of decedents prescribed psychoactive medications, one prescribed dothiepin had 
ingested cocaine and piperazines, and another prescribed amitriptyline had used mephedrone. Neither of 
these or any other cases appear to have experienced such a complication.
3.3.5 Drug effects and mental health issues
In the 1960s GHB showed promising effects on agitation and depression, acting as an anxiolytic and an 
antidepressant.  However, with the growing use of benzodiazepines and tricyclic antidepressants, GHB 
was forgotten about in this context. However, in recent years it has started to be reconsidered as an anti-
depressant and/or in the treatment of depressive disorders (Bosch et al., 2012; Snead and Gibson, 2005).   
Bosch et al. 2012 suggest that GABAergic mechanisms with secondary effects on serotonin, 
norepinephrine and dopamine systems may contribute to the antidepressant qualities of GHB. However, 
there may be an additive effect between sodium oxybate and antidepressants, with increased likelihood of 
adverse incidents with tricyclic antidepressants (Gerot Lannach, 2011).
Where known, one-third (32%) of the decedents in this sample were prescribed psychoactive medications, 
mostly antidepressants, antipsychotics or hypnotics/sedatives, often in combination (Table 2). This 
appears to be a higher proportion than in the general population. A survey conducted in June 2011 
suggests that 13% of adult females and 10% of adult males in the UK were currently taking 
antidepressants (Our insight, 2011). This is echoed in Scotland where 15% of the population have taken 
such drugs (Herbert, 2014), and 9% reported by Blanchflower and Oswald (2011). Overall, one percent of 
UK patients in primary care received an antipsychotic between 1995 and 2011 (Marston et al., 2014). In 
the latest General Household Survey, in 2007, asking about prescription medications, 0.5% reported using 
tranquillisers in the previous year (ONS, 2009). Thus is similar to the level of 0.5% last year use of illegal 
tranquillisers reported by households on England and Wales in 2013/14 (Home Office, 2014).
This observation of prescribed medications points to these individuals having pre-existing psychiatric 
disorders. In fact, an examination of the 29 cases supports this. Depression is mentioned in six cases, 
suicidal ideation/suicide attempts in four cases, misuse of drugs or dependence in five cases, alcoholism 
in two cases, bipolar disorder in two cases, psychosis in one case, and paranoia in one case. Fourteen
(48.3%) of these 29 cases had one or more of these conditions. In the remaining 130 cases depression 
was only mentioned six times, psychosis twice, paranoia once, and anxiety with depression once. 
Previous suicide attempts had been made by four of those prescribed medication compared to only three 
of the remaining 130 decedents.
Overall, 69.0% of those on medication had at least one prescribed medication found in the post-mortem 
toxicology, but only 34.5% of the medications were implicated in death. When the number of prescribed 
drugs is considered, these proportions fall to 44.3% and 21.3% respectively. The highest proportions were 
found amongst those prescribed opioids, benzodiazepines (diazepam), non-benzodiazepine hypnotics 
and antipsychotics. The combination of such prescribed medications along with GHB/GBL use underlines 
the dangers of potential drug interactions. These findings for those on medications echo the literature 
described earlier in respect of sodium oxybate patients in terms of substance abuse, dependence, 
withdrawal symptoms, and overdose with suicidal intent (Wang et al., 2009). 
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Case studies indicate that sodium oxybate on its own has led to depression and anxiety with suicidal 
ideation (Ortega-Albás et al., 2010), psychosis (visual hallucinations, paranoid delusions, derealisation,
hyper-religiosity, and anxiety; Langford and Gross, 2011) and traumatic suicide attempts (Chien et al., 
2013). In conjunction with modafinil this may lead to depression, derealisation, and suicidal ideation 
(Rossetti et al., 2010). These clinical symptoms appear to resolve with reduced dosages and re-titration or 
total withdrawal of sodium oxybate. Although the pathogenic mechanism in such cases is unknown, 
Rossetti et al. (2010) suggest it may be due to the substance acting on GABAB receptors. Depression was 
reported by patients receiving sodium oxybate (U.S. Xyrem® Multicenter Study Group, 2003), and anxiety 
by patients receiving both sodium oxybate and modafinil (Black and Houghton, 2006).    
There are issues around withdrawal of GHB (Langford and Gross, 2011; McDaniel and Miotto, 2001; van 
Noorden et al., 2014), both from clinical doses as well as recreational doses. Severe cases of withdrawal 
can feature extreme agitation, delirium and rhabdomyolysis and should be regarded as medical 
emergencies (van Noorden et al., 2014). Case studies of GHB withdrawal show similar symptoms to the 
effects of high doses of sodium oxybate: agitation, anxiety, delirium with disorientation, auditory/visual 
hallucinations, fluctuations in/disturbance of consciousness. Paranoid delusions; hypertension, 
tachycardia and seizures can also occur (van Noorden et al., 2014). Return to GHB or GBL use may 
occur soon after treatment of withdrawal as patients seek to overcome their cravings not only for 
GHB/GBL but also for alcohol, opioids (including heroin/morphine) and cocaine (Bosch et al., 2012), etc. 
through self-medication or by increasing dosages of sodium oxybate above the recommended dosages 
(Beghè and Carpanini, 2000).
3.3.6 Drug interactions
There are several known interactions between GHB and other drug(s), e.g. drug-drug interactions. 
Antiretrovirals such as ritonavir and saquinavir inhibit the cytochrome p450 system, which may decrease 
first-pass hepatic metabolism of GHB, leading to the potentiation of its effects, i.e. slow down its 
elimination and allow levels to build up (Mason and Kerns, 2002). This complication could be important to 
communicate to those in the gay community receiving antiretrovirals who may wish to use GHB or its 
derivatives. GHB has a potentially important synergistic interaction with PCP and ketamine, as they act as 
NMDA receptor antagonists (Sevak et al., 2004). Possible interactions may occur between sodium 
oxybate and drugs that induce or inhibit the GHB dehydrogenase enzyme; these could include 
antiepileptics such as sodium valproate, phenytoin and ethosuximide (Gerot Lannach, 2007). Whereas 
Navarro et al. (1998) suggested a synergistic interaction between GHB and the neuroleptic haloperidol, 
Sevak et al. (2004) did not. SSRIs, such as the antidepressants citalopram and fluoxetine were here 
prescribed to a number of decedents; however the literature does not suggest any SSRI/GHB interactions. 
Many of those prescribed psychiatric medications in the sample described above (Section 3.3.5) were
prescribed medications (Table 2) with possible interactions with GHB/sodium oxybate.
The Patient Information Leaflet for Xyrem® states the medication is contraindicated for “patients being 
treated with opioids or barbiturates” (EMEA, 2014). It also advises that patients be warned about the use 
of alcohol in conjunction with sodium oxybate, and to avoid concomitant use of benzodiazepines because 
of the CNS-depressant effects. The general advice is not to use it in combination with sedative hypnotics,
other CNS depressants or antiepileptics; or by those suffering from epilepsy or epileptiform seizures. Use 
of sodium oxybate is also contraindicated for those with previous or current addiction to opioids and other 
CNS depressants, those with a previous cocaine addiction (Caputo et al., 2009), or those with mental 
health issues/disorders (Gerot Lannach Pharma, 2007; Laboratorio Farmaceutico C.T.Srl., 2007; Murali 
and Kotagal, 2006). The UK cases examined here included individuals contraindicated for such 
combinations. This highlights the need for such interactions to be brought to the attention not only of 
patients treated with sodium oxybate but also to recreational users of GHB and its derivatives.
Self-medication by GHB/GBL has not only been reported to treat depression but also for sleep disorders, 
bodybuilding, and alcohol-related disorders (Mason and Kerns, 2002), and in this study to aid relaxation. 
This study reinforces the contribution this phenomenon makes to GHB/GBL related overdoses and 
fatalities.
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The role of alcohol in potentiating the depressive effects of GHB/GBL has been widely documented 
(Adinoff et al., 1988; Altose and Hudgel, 1986; Mason and Kerns, 2002; Zvosec et al., 2011). The dangers 
of mixing GHB/GBL with alcohol and/or other CNS-depressant substances need to be better described in 
prevention campaigns. Recreational users need to be reminded of the dangers of this substance, 
especially when taken in combination with other substances, including stimulants. The dangers of using 
GHB, on its own and in combination with other substances, have become more widely recognised and 
disseminated in the last decade (e.g. ACMD, Mixmag magazine, initiatives in Vauxhall clubs, etc.). These 
activities, together with the classification of GHB as a Class C drug in 2003 and subsequently its prodrugs 
in 2009 may have contributed to the fall in use recorded by the Mixmag Survey over the past decade, and 
the decline in recent years to the number of TOXBASE sessions and telephone inquiries received by the 
NPIS (2013). However, the number of deaths rose again in 2012. The potential dangers of GHB/GBL 
consumption need to be brought to the attention of would-be users.
3.3.7 Limitations
A number of further limitations have to be borne in mind when interpreting these findings.  The submission 
of data is done on a voluntary basis. Thus, as explained above (Section 3.1.1), coverage by NPSAD of 
coroners' jurisdictions is not complete but has remained at a consistently high level over the past decade 
or more. To counter this limitation, other sources of information are used, including newspaper articles, as 
well as historic checks with all of the General Register Offices in the UK.  Since those who die from GHB 
use appear to differ in a number of ways from 'typical' victims of drug-related deaths, it is possible that 
Investigators may have missed other cases. These factors may mean that the cases reported here are a 
skewed sample and an underestimate of actual deaths during this period. However, they are probably 
representative of UK fatalities involving GHB and its derivatives. 
We believe that we have minimised the risk of false-positives by either including cases above our cut-off 
levels and/or where there was clear evidence of exogenous sources. However, false-negatives may have 
been excluded due to adherence to high cut-off levels. There are problems in trying to assess the exact 
risk of death due to toxicity from GHB and its analogues: the inclusion of only cases where exogenous 
GHB is implicated, e.g. based on interpretation of post-mortem blood and urine concentrations; and 
polysubstance use as well as evidential data overcome this issue. However, as this study clearly 
demonstrates, it is possible to attribute deaths directly to consumption of these substances. Their use still 
continues.
4 Conclusions
This is the most comprehensive and detailed report of UK fatalities associated with non medical use of 
GHB and its derivatives produced to date. Evidence emerging from the NPSAD and other UK databases
shows that such deaths are continuing despite legal controls on their possession and trade. Many GHB 
deaths involve alcohol and other CNS depressants. These themes are consistent with cases reported in 
other countries, chiefly the US, Australasia, and Europe, where GHB has been used in similar ways. 
However, this study indicates that many cases involve the co-ingestion of stimulants and ketamine.
The misuse of GABA-analogues such as baclofen, gabapentin and pregabalin is also a related concern in 
Europe and the UK (Schifano et al., 2015; Kapil et al., 2013). There is some evidence of all three being 
misused in the UK (Kapil et al., 2015). Three of the present sample reported on were prescribed 
gabapentin (Table 2). The combination of a therapeutic level of baclofen and GHB can lead to coma, 
bradypnoea and hypotonia. The overlapping neurobiological pathway can enhance the agonist role of 
GHB (Kamal et al., 2015).
NMP (Reisch, 2008), and similar molecules, including GHV (Brunt et al., 2013; Carter et al., 2005), 
phenibut (O’Connell et al., 2014; Samokhvalov et al., 2013; Schmitt et al., 2013) and baclofen (Franchitto 
et al., 2014; Gahr et al., 2014; Weißhaar et al., 2012) are now starting to emerge as substitutes for 
GHB/GBL. Some internet sites that formerly offered GHB and GBL for sale to assist sleep, as an aid in 
bodybuilding, for energy boosts, as an antidepressant, etc. have discontinued these lines. Instead they 
offer (August 2014) “Ghb Furanone Alternatives” such as “U4EA X”, “Legato”, Renew G”, “Liquid 
Relaxation”, “Gabatrol-90” (www.ghb-furanone.com; www.eurolab-replenish.com). The GHB analogue 
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GHV (gamma-hydroxyvaleric acid) may also be seen as an alternative molecule to take, being advertised 
as a dietary supplement (Penberthy et al., 2010). 
Although these ‘legal alternatives’ come with detailed warnings about careful use and lists of ingredients, it 
seems sensible to advise potential consumers of the inherent risks in taking such substances. Medical 
practitioners and other health professionals need to be aware of the likelihood of coming across patients 
consuming GHB and related substances (typically in combination with CNS depressant substances and/or 
stimulants), and of their severe and often unpredictable effects, including their addiction potential and 
withdrawal issues. 
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Figure 1: Evolution of UK deaths associated with the use of GHB, GBL and 1,4-BD reported to 
NPSAD by September 2013
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Relevant cases 1 0 1 2 3 2 7 6 1 3 5 11 17 18 25 21 9 20 7
GHB/GBL in PM 1 0 1 2 3 2 7 6 1 3 5 11 17 18 24 21 8 20 7
GBL implicated 0 0 0 0 0 0 0 2 0 1 1 3 4 6 12 16 5 4 1
GHB/GBL implicated 1 0 1 2 3 2 7 6 1 3 5 11 17 18 24 21 9 20 7
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Table 1: Socio-demographics of UK deaths associated with GHB, GBL and 1,4-BD reported to 
NPSAD by September 2013
Variable Category Number (%)
Total 159 (100.0)
Gender Male 130 (82.4)
Female 29 (17.6)
Sexual orientation Confirmed homosexual 17 (10.6)
Possible homosexual 2 (1.3)
Transgender/Transvestite 2 (1.3)
Country of birth England 78 (49.1)
Wales 8 (5.0)
Scotland 8 (5.0)
Europe 13 (8.2)
Americas 5 (3.1)
Africa 4 (2.5)
Asia 4 (2.5)
Australia 1 (0.6)
Not known 37 (23.3)
Employment status Unemployed 22 (13.8)
Employed 87 (54.7)
Student 9 (5.7)
House person/carer 3  (1.9)
Retired/sickness/invalidity 2 (1.3)
Not known 36 (22.6)
Living arrangements Alone 43 (27.0)
With others 82 (51.6)
No fixed abode 1 (0.6)
Other 1 (0.6)
Not known 32 (20.1)
Ethnicity White 113 (71.1)
Black African 1 (0.6)
Black Caribbean 1 (0.6)
Indian 1 (0.6)
Chinese 1 (0.6)
Other 6 (3.8)
Not known 36 (22.6)
History of drug use Yes 74 (46.5)
No 32(20.1)
Not known 53 (33.3)
Injecting status Yes 10 (6.3)
No 46 (28.9)
Not known 103 (64.8)
Age-group (years) 15-24 36 (22.6)
25-34 70 (44.0)
35-44 38 (23.9)
45-54 14 (8.8)
55-64 1 (0.6)
Age at death (years) Male Mean 32.63; Min 18.88, Max 60.10, SD 8.58
Female Mean 29.91; Min 19.00, Max 47.31, SD 8.24
All Mean 32.13; Min 18.88, Max 60.10, SD 8.56
Page 52 of 61
Ac
ce
pte
d M
an
us
cri
pt
52
Table 2: GHB/GBL cases with specified prescribed psychoactive medications reported to NPSAD 
by September 2013
Substance category Medication Number
ADHD drug Amphetamine 1
Dexamphetamine 1
Modafinil 1
Antidepressant Venlafaxine 3
Dothiepin (tricyclic) 2
Citalopram (SSRI) 5
Mirtazapine 4
Duloxetine 2
Amitryptyline (tricyclic) 1
Fluoxetine (SSRI) 2
Antiepileptic Gabapentin 3
Sodium valproate 1
Clonazepam 1
Antihistamine Cyclizine 1
Cetirizine 1
Antimanic Lithium 1
Antipsychotic Olanzapine 2
Chlorpromazine 1
Quetiapine 3
Risperidone 1
Sulpiride 1
Haloperidol 1
Anxiolytic Chlordiazepoxide 1
Benzodiazepine Diazepam 8
Non-Benzodiazepine hypnotic Zopiclone 4
Zolpidem 1
Zaleplon 1
Opioid Co-proxamol 1
Co-codamol 2
Tramadol 2
Buprenorphine 1
Sex hormones Testosterone 1
Total cases 29
Notes: Rows may sum to more than the total as same individuals may have been prescribed more than one medication.
SSRI: Selective Serotonin Re-uptake Inhibitor
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Table 3: Geographic areas of place of UK deaths associated with GHB, GBL and 1,4-BD reported to 
NPSAD by September 2013
Area Number %
Northern Ireland 0 0.0
Isle of Man 0 0.0
Jersey 0 0.0
Guernsey 0 0.0
Wales 9 5.7
    of which, Rhondda Cynon Taf 3 1.9
     Cardiff 2 1.3
Scotland 27 17.0
    of which, Lothian & Borders 17 10.7
     Strathclyde 6 3.8
England 123 77.4
Greater London 40 25.2
Bromley 1 0.6
Camden 2 1.3
Croydon 1 0.6
Enfield 1 0.6
Greenwich 2 1.3
Hammersmith & Fulham 1 0.6
Islington 2 1.3
Lambeth 15 9.4
Newham 2 1.3
Southwark 2 1.3
Tower Hamlets 2 1.3
Waltham Forest 1 0.6
Westminster 7 4.4
Other selected areas
Brighton & Hove 4 2,5
Kirklees 3 1.9
Manchester 3 2.5
Shropshire 4 2.5
N 159 100.0
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Table 4: Circumstances of UK deaths associated with GHB, GBL and 1,4-BD reported to NPSAD by 
September 2013
Variable Category Number (%)
Total 159 (100.0)
Place of death At home 80 (50.3)
Private residential address 31 (19.5)
Hotel/Hostel 4 (2.5)
Hospital 21 (13.2)
Street/road 1 (0.6)
Open space, woodland, camp-site 3 (1.9)
River/stream/lake 1 (0.6)
Motor vehicle 2 (1.3)
Gay sauna 1 (0.6)
Not known 15 (9.4)
Verdict (conclusion) Accident/Misadventure 95 (59.7)
Suicide 11 (6.9)
Open/Undetermined 18 (11.3)
Non-dependent abuse of drugs 22 (13.8)
Abuse of drugs 8 (5.0)
Dependence on drugs 5 (3.1)
Manner of death Accidental 126 (79.2)
Suicidal 11 (6.9)
Undetermined 21 (13.2)
Unclassified 1 (0.6)
Circumstances of death/events leading to 
death
Recreational drug use/party - at home 44 (27.7)
Recreational drug use/party – other private residence 17 (10.7)
Recreational drug use/party – pub/club 16 (10.1)
Recreational drug use/party - at festival 1 (0.6)
Recreational drug use/party – in car 2 (1.3)
Recreational drug use/party – public place 1 (0.6)
Recreational drug use/party – gay health spa 1 (0.6)
Body-building fitness 3 (1.9)
Aid sleep 3 (1.9)
Body-building & aid sleep 1 (0.6)
Prevent craving for alcohol & aid relaxation 1 (0.6)
Dependent use – trying to wean self off 1 (0.6)
Accidentally mistaken for water 5 (3.1)
Drank from drink not intended for deceased 2 (1.3)
Drank undiluted accidentally 1 (0.6)
In sexual activity 6 (3.8)
Suicide 7 (4.4)
Open verdict 2 (1.3)
Cut own neck under influence of GHB 1 (0.6)
Not known 44 (27.7)
Location of events leading to death Home 81 (50.9)
Other specified place 50 (31.4)
Of which, friends/relative’s home 21 (13.2)
    Third party’s home 6 (3.8)
    Hotel 4 (2.5)
    Car 4 (2.5)
    Open space/canal/street 4 (2.5)
    Gay health spa 2 (1.3)
Other 9 (5.7)
Not known 28 (17.6)
Day of death Sunday 35 (22.0)
Monday 22 (13.8)
Tuesday 22 (13.8)
Wednesday 18 (11.3)
Thursday 15 (9.4)
Friday 18 (11.3)
Saturday 29 (18.2)
Number of PM drugs N =158 Mean 3.47, Median 3; 
Mode 3; Min 0, Max 13, 
SD 2.14
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Table 5: Proximal and Underlying cause of deaths associated with GHB, GBL and 1,4-BD reported 
to NPSAD by September 2013
ICD-10 
code
Description Proximal 
cause
Underlying 
cause
Number (%) Number (%)
Mental & behavioural disorders due to psychoactive substance use
F15.0 Use of stimulants – acute intoxication 0 (0.0) 1 (0.6)
F19.1 Multiple drug use – harmful use 0 (0.0) 1 (0.6)
F19.2 Multiple drug use - dependence 1 (0.6) 1 (0.6)
Accidental poisoning
X40 Non-opioid analgesics, anti-pyretics and anti-rheumatics 0 (0.0) 1 (0.6)
X41 Anti-epileptic, sedative-hypnotic, anti-Parkinsonism and psychotropic drugs, not 
elsewhere classified
92 (57.9) 106 (66.7)
X42 Narcotics and psychodysleptics (hallucinogens), not elsewhere classified 2 (1.3) 12 (7.5)
X44 Other and unspecified drugs, medicaments and biological substances 1 (0.6) 2 (1.3)
Intentional self-poisoning
X61 Anti-epileptic, sedative-hypnotic, anti-Parkinsonism and psychotropic drugs, not 
elsewhere classified
8 (5.0) 8 (5.0)
X62 Narcotics and psychodysleptics (hallucinogens), not elsewhere classified 1 (0.6) 2 (1.3)
Poisoning of undetermined intent
Y11 Anti-epileptic, sedative-hypnotic, anti-parkinsonism and psychotropic drugs, not 
elsewhere classified
14 (8.8) 19 (11.9)
Y12 Narcotics and psychodysleptics (hallucinogens), not elsewhere classified 0 (0.0) 1 (0.6)
Other causes
G93.1 Brain damage, anoxic or hypoxic 1 (0.6) 0 (0.0)
G97.8 Cerebral hypoxia, unspecified 2 (1.3) 0 (0.0)
I25.1 Atherosclerotic heart disease 1 (0.6) 0 (0.0)
I26.9 Pulmonary embolism 1 (0.6) 0 (0.0)
I50.1 Left ventricular failure 1 (0.6) 0 (0.0)
I50.9 Cardiac failure, unspecified 2 (1.3) 0 (0.0)
J18.0 Bronchopneumonia 1 (0.6) 0 (0.0)
J18.9 Pneumonia, unspecified 1 (0.6) 0 (0.0)
J43 Emphysema 1 (0.6) 0 (0.0)
J69.0 Aspiration pneumonia 1 (0.6) 0 (0.0)
J81.0 Pulmonary oedema or congestion 1 (0.6) 0 (0.0)
J96.0 Acute respiratory failure 1 (0.6) 0 (0.0)
J96.9 Respiratory failure/depression 3 (1.9) 0 (0.0)
J98.8 Other specified respiratory disorder 1 (0.6) 0 (0.0)
K22.2 Ulcer of oesophagus 1 (0.6) 0 (0.0)
K76.0 Fatty change of liver, not elsewhere specified 0 (0.0) 1 (0.6)
R09.0 Asphyxia general 2 (1.3) 0 (0.0)
R09.2 Cardiorespiratory failure/arrest 4 (2.5) 0 (0.0)
S02.9 Fracture of skull & facial bones, part unspecified 1 (0.6) 0 (0.0)
S15 Injury of blood vessels at neck level 1 (0.6) 0 (0.0)
T07 Multiple injuries, unspecified 1 (0.6) 0 (0.0)
T17.9 Aspiration of gastric contents 4 (2.5) 0 (0.0)
W66 Drowning/submersion whilst in bath 2 (1.3) 0 (0.0)
W69 Drowning whilst in natural water 1 (0.6) 1 (0.6)
W78 Aspiration of gastric contents 2 (1.3) 0 (0.0)
X70 Intentional hanging 1 (0.6 1 (0.6)
R99 Unascertained 1 (0.6) 1 (0.6)
All codes 159 (100.0) 159 (100.0)
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Table 6: Blood levels of GHB/GBL by post-mortem substance combinations reported to NPSAD by 
September 2013
Substance combination Mentions of 
GHB/GBL
Information available 
on levels
GHB/GBL blood levels (mg/L)
No (%) No (%) Mean Minimum Maximum Std Dev
GHB implicated but not in PM 1 (0.6) 0 (0.0) - - - -
GHB implicated alone & sole drug in 
PM
27 (17.0) 13 (48.1) 1057.62 159 6500 1690.06
GHB implicated alone & other drugs 
in PM
16 (10.1) 12 (75.0) 531.42 45 2355 623.05
GHB implicated alone & other drugs 
and alcohol in PM
15 (9.4) 12 (80.0) 516.50 116 1400 413.96
GHB and alcohol only implicated & 
sole substances in PM
8 (5.0) 8 (100.0) 906.63 131 2794 1078.10
GHB and alcohol only implicated & 
other drugs in PM
14 (8.8) 11 (78.60) 326.35 0 1222 334.44
GHB and other drugs implicated & no 
alcohol in PM
38 (23.9) 32 (84.2) 354.92 > 10 1400 418.86
GHB and other drugs implicated & 
alcohol in PM
7 (4.4) 5 (71.4) 298.00 106 597 180.50
GHB and other drugs and alcohol 
implicated
23 (14.5) 17 (73.9) 451.64 30 2313 554.52
GHB not implicated but in PM after 
consumption
10 (6.3) 10 (100.0) 59.40 8 233 66.76
Total 159 (100.0) 121 (76.1) 481.70 8 6500 758.26
Page 57 of 61
Ac
ce
pte
d M
an
us
cri
pt
57
Table 7: Combinations of post-mortem drugs in deaths associated with GHB, GBL and 1,4-BD 
reported to NPSAD by September 2013
Commonest substance combination No (%)
GHB/GBL + alcohol 22 (13.8)
GHB/GBL + stimulant 20 (12.6)
GHB/GBL + stimulant + alcohol 19 (11.9)
GHB/GBL + stimulant + benzodiazepine 7 (4.4)
GHB/GBL + stimulant + benzodiazepine + alcohol 7 (4.4)
GHB/GBL + benzodiazepine + alcohol 7 (4.4)
GHB/GBL + stimulant + ketamine 6 (3.8)
GHB/GBL + stimulant + benzodiazepine + opiate/opioid 5 (3.1)
GHB/GBL + benzodiazepine + opiate/opioid + alcohol 4 (2.5)
GHB/GBL + opiate/opioid 4 (2.5)
GHB/GBL + opiate/opioid + alcohol 4 (2.5)
Percentages of common substances: alcohol (45.9); diazepam (26.4); cocaine (23.9); MDMA/MDA (14.5); 
amphetamine (13.2); cannabinoids (10.1); ketamine (8.8); morphine/codeine (8.8); mephedrone (7.5)
N = 159 
Note: The percentages given for single substances made sum to more than the total as some cases had more than 
one substance found at post-mortem
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Table 8: Cases involving GHB/GBL alone reported to NPSAD by September 2013
Key characteristic Number (n = 59)
Male 52 (88.1%)
Age at death (years) Mean = 32.21; Min = 19.00; Max = 52.57; SD = 8.78
Ethnicity White = 41 (69.5%), Black Caribbean = 1 (1.7%), Chinese = 1 (1.7%); other = 3 
(5.1%), Not known = 13 (22.0%)
History of drug use Yes = 24 (40.7%); no =  12 (20.3%); Not known = 23 (40.0%)
Place of incident leading to death Home = 28 (47.5%); Other specified place = 14 (23.7%); Street/road = 1 (1.7%); 
Sauna 1 (1.7%); Not known  = 15 (25.4%)
Place of death At home = 29 (49.2%); hospital = 8 (13.6%); Private residence = 7 (11.9%); open 
space = 3 (5.1%); Street/road = 1 (1.7%); Car = 1 (1.7%); Sauna = 1 (1.7%); Not 
known = 9 (15.3%)
Year of death 1991 – 1; 2001- 2; 2004 = 2; 2005 =2; 2006 = 3; 2007 = 6; 2008 = 6; 2009 = 9; 
2010 = 9; 2011 = 5; 2012 = 10; 2013 = 4
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Table 9: Dosage and levels of GHB/GBL in human tissues 
Study, enrolment Dosage (oral route unless 
specified)
GHB level (mg/L) in 
plasma (unless 
specified)
Other substances and levels
Dosages
Marinetti, 2001 Therapeutic Bl 24-88 mg/L
Palatini et al., 1993 Drowsiness – 25 mg/kg (oral) – 80 
mg/L peak plasma
Baselt, 2008 Amnesia  - 10 mg/kg; sleep/deep 
sedation – 20-30 mg/kg; recreational 
– 35 mg/kg; anaesthesia - >50mg/L
Helrich et al., 1964 Sleep – 50 mg/kg (IV) peak blood 
170 mg/L
Hoes et al., 1980 Sleep – 75mg/kg (oral) peak plasma 
at 2 h 90 mg/L, plasma at 6 h 9 
mg/L; 100 mg/kg (oral) ur peak at 4 
h 1100 mg/L
Baselt, 2008 Sleep/deep sedation - 20-30 mg/kg
Baselt, 2008 Recreational – 35 mg/kg
Baselt, 2008 Anaesthesia - >50mg/L
Endogenous PM GHB
Busardò et al., 2014 Deaths with no GHB ingestion
Femoral blood (N = 30) Range 0.54-24.12
Urine (N = 30) Range 0.58-22.13 
Kintz et al., 2004 Deaths with no GHB ingestion
Cardiac blood (N = 71) Range 0.4-409; mean 
36.7; median 17.5
Femoral blood (N = 5) Range 16.8-44.1, mean 
30.4; median 34.3 
Elliott, 2004a Deaths with no GHB ingestion
Femoral blood (N = 35) Range 2-29; mean 12.6; 
median 12
Moriya & Hashimoto, 2005 Deaths with no GHB ingestion
Left cardiac chamber blood 
(N = 21)
Range ND-15.8, mean 
4.0; median 3.1
Right cardiac chamber blood 
(N = 19)
Range ND-14.4; mean 
4.9; median 4.3
Aortic blood (N = 20) Range ND-23.7; mean 
4.0; median 2.5 
Femoral venous blood (N = 
23)
Range ND-11.6; mean 
4.6; median 4.7
Elliott, 2001 Deaths with no GHB ingestion Range 0-197
Fieler et al., 1998 Deaths with no GHB ingestion 3.2-168
Marinetti et al., 2005 Deaths with no GHB ingestion 11-97
Moriya & Hashimoto, 2004 Deaths with no GHB ingestion 0-43.0
Stephens et al., 1999 Deaths with no GHB ingestion 5-77
Anaethesia study
Helrich et al., 1964
Surgical patients (N = 14) 100mg/kg of GHB, intravenous, no 
pre-meds or other drugs 
administered
Peak blood level range 
234-520; mean 307
Pharmacokinetic studies
Borgen et al., 2000
Vounteers (N = 12), divided 
doses of Xyrem® 
administered 4 h apart
Regimen 1 (4.5 g total) GHB
Dose 1 – 2.25 g GHB Mean peak 26.6
Dose 2 – 2.25 g GHB Mean peak 60.1
Regimen 2 (9 g total) GHB
Dose 1 – 4.5 g GHB Mean peak 77.6
Dose 2 – 4.5 g GHB Mean peak 141.9
Brenneisen et al., 2004
Volunteers (N = 8) 25 mg/kg GHB Peak range 4.7-76.3; 
mean peak 39.7 (SEM 
10.6)
Thai et al., 2007
Volunteers (N = 8) 25 mg/kg GHB Peak range 22.2-85.7; 
mean peak 45.6 (SD 
19.7)
Thai et al., 2006
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Volunteers (N = 16) 50 mg/kg GHB Mean peak 72.6 (SD 
16.2)
Abanades et al., 2006
Volunteers (N = 8) 40 mg/kg (N=4) GHB Mean peak 79.1 (SD 
26.4)
50 mg/kg (N=5) GHB Mean peak 83.1 (SD 
28.8)
60 mg/kg (N=4) GHB Mean peak 113.5 (SD 
20.1)
72 mg/kg (N=2) GHB Mean peak 130.1 (SD 
10.7)
Non-fatal GHB toxicity 
cases
(Sample drawn in 
Emergency Department)
Dyer et al., 1994 Unknown dose 101 Negative for co-intoxicants
Couper & Logan, 2000 Unknown dose 130 Negative for co-intoxicants
Zvosec et al., 2001 Unknown dose (BD) 317 (GHB dependent) Negative for co-intoxicants
Megarbane et al., 2002 Unknown dose (BD) 222 (regular GHB user) Negative for co-intoxicants
Couper et al., 2004 Unknown dose (BD) Bl mean 137, median 
103, min 29, max 490 
mg/L
Negative for co-intoxicants
Strickland et al., 2005 Unknown dose (BD) 1200 Negative for co-intoxicants
Lenz et al., 2008 Unknown dose (GBL) 161 Negative for co-intoxicants
Dargan et al., 2008 600mg/kg of Xyrem 569 (serum) 7 h post 
ingestion; 377 8.5 h post 
ingestion
Negative for co-intoxicants
Driving samples
Driving under the influence
Stephens and Baselt, 1994; 
Couper and Logan, 2001, 
2004
Bl mean 97, median 95, 
range 26-255 mg/L
Pan et al., 2001 Bl 16-350 mg/L
Bosman and Lusthof, 2003 Bl 51-195 mg/L, ur 100-
2000 mg/L
Jones et al., 2007 Bl mean 90, median 84,
max 340mg/L
Al-Samarrie et al., 2010 Bl median 1262, range 
592-2191mu mol/L
Burch et al., 2013 (N = 5) Bl 80-190, mean 126, 
median 120 mg/L
Drug users
Jones et al., 2007 Bl median 118, max 840 
mg/L
Intoxications
Elliott, 2004b (N = 27); M = 
25, age = 12-44, where 
known 
Unknown dose Bl mean 245, range 86-
551; ur 1732, range 5-
5581 
Ethanol (7); drugs (15)
GHB-associated fatalities
Duer et al., 2001 Unknown dose 303 Negative for co-intoxicants
Harty & Kemp, 2002 Unknown dose 1270 Negative for co-intoxicants
Caldicott et al., 2004 Unknown dose PM 77; AM 210, 220 Negative for co-intoxicants
ACMD, 2007
N = 6* in NPSAD sample Unknown dose PM 42, 120, 159, 403, 
1575; AM 430
Negative for co-intoxicants
Lenz et al., 2008 Unknown dose 165 Negative for co-intoxicants
Medical examiner cases
Jones et al., 2007 (N = 33) Bl mean 307, median 
190, max 2200 mg/L
Known GHB uptake Peripheral blood
Kalasinsky et al., 2001 330
Kintz et al., 2005 Femoral bl 2937 ; cardiac 
bl 3385 (ur 33; bile 727; 
vit. 1800 and 2856)
Femoral blood MDMA 144 
ng/mL
Mazarr-Proo & Kerrigan, 
2005
461
Baselt, 2008 27-1030
Lenz et al., 2008 165, 957
Knudsen et al., 2010 170-2200 No or minor influence of other 
drugs
Kraner et al., 2010 280
Zvosec et al., 2011
Periphereal & heart Range 18-4400; median 
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Zvosec et al., 2009
N = 3 Xyrem® 141 Alcohol 0.02%; phentermine 
0.26; zolpidem 0.16; 
paroxetine 0.3
Xyrem® 110 Alprazolam 0.016; 
nordiazepam 0.081; quetiapine 
0.045
Xyrem® 3500 Methylamphetamine 1.1; 
amphetamine 0.19; 
chlorpheniramine <0.05
Akins et al., 2009 Xyrem® 165.6, 140 (ur 90.7; 
gastric 142.0)
Tramadol 0.46; carisprodol 1.9; 
meprobamate 3.9
Ferrara et al., 1995 Alcover® 11.5 (ur 258.3; vit 84.3) Morphine 0.77 (vit. 0.3); 6-
MAM 28.5
